

Simultaneous modeling of pharmacokinetics and pharmacodynamics of d-tubocurarine

Clinical Pharmacology and Therapeutics  
25, 358-371

DOI: 10.1002/cpt1979253358

Citation Report

#	ARTICLE	IF	CITATIONS
1	Exploring biological signals. , 1986, , 315-338.		0
2	Multiple receptor responses: A new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: Studies on clonidine in the rat and cat. Journal of Pharmacokinetics and Pharmacodynamics, 1979, 7, 495-510.	0.6	37
3	The Modelling of Drug Response. Clinical Science, 1980, 59, 311-315.	1.8	50
4	Pharmacokinetic studies in man with gallamine triethiodide. European Journal of Clinical Pharmacology, 1980, 17, 135-143.	0.8	19
5	Pharmacokinetic studies in man with gallamine triethiodide. European Journal of Clinical Pharmacology, 1980, 17, 145-152.	0.8	15
6	Modeling of drug response in individual subjects. Journal of Pharmacokinetics and Pharmacodynamics, 1980, 8, 115-130.	0.6	44
7	DO WE NEED A THREE-COMPARTMENT MODEL FOR THE PREDICTION OF DIGOXIN BLOOD LEVELS ON MULTIPLE DOSING?. Journal of Clinical Pharmacy and Therapeutics, 1980, 5, 31-34.	0.7	1
8	Drug Pharmacokinetics in Cardiac and Hepatic Disease. Annual Review of Pharmacology and Toxicology, 1980, 20, 389-413.	4.2	45
9	Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides.. British Journal of Clinical Pharmacology, 1980, 10, 135-143.	1.1	25
10	Quantitative analysis of the disopyramide concentration-effect relationship.. British Journal of Clinical Pharmacology, 1980, 9, 67-75.	1.1	73
11	Understanding the Dose-Effect Relationship. Clinical Pharmacokinetics, 1981, 6, 429-453.	1.6	994
12	Clinical Pharmacokinetics of the Non-depolarising Muscle Relaxants. Clinical Pharmacokinetics, 1981, 6, 25-60.	1.6	20
13	Pharmacokinetics in Intravenous Anaesthetic Practice. Clinical Pharmacokinetics, 1981, 6, 61-82.	1.6	21
14	Estimation of pharmacokinetic parameters: Statistical considerations. , 1981, 13, 543-556.		17
15	The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentrationâ€effect relationships.. British Journal of Clinical Pharmacology, 1981, 11, 187-195.	1.1	121
16	Modelling theophylline response in individual patients with chronic bronchitis.. British Journal of Clinical Pharmacology, 1981, 12, 481-487.	1.1	25
17	Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.. British Journal of Clinical Pharmacology, 1981, 12, 51-60.	1.1	116
18	Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology, 1981, 75, 158-164.	1.5	77

#	ARTICLE	IF	CITATIONS
19	Simultaneous pharmacokinetic and pharmacodynamic modeling. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 367-388.	0.6	92
20	An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 27-40.	0.6	10
21	A standard approach to compiling clinical pharmacokinetic data. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 59-127.	0.6	30
22	RELATIONSHIP BETWEEN DECAY OF PLASMA CONCENTRATION OF FAZADINIUM AND RECOVERY FROM ITS NEUROMUSCULAR BLOCKING EFFECT. British Journal of Anaesthesia, 1981, 53, 853-858.	1.5	4
23	DOSE-RESPONSE CURVES FOR FOUR NEUROMUSCULAR BLOCKERS USING CONTINUOUS I.V. INFUSION. British Journal of Anaesthesia, 1981, 53, 627-633.	1.5	10
25	AGE-DEPENDENT DOSE-RESPONSE RELATIONSHIP OF ORG NC45 IN ANAESTHETIZED PATIENTS. British Journal of Anaesthesia, 1982, 54, 653-657.	1.5	88
26	Pharmacokinetics: The Role of Compartmental Models. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1982, 15, 1033-1038.	0.4	5
27	A Model for Use in Automated Control of Muscle Relaxation During Surgical Procedures. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1982, 15, 1229-1234.	0.4	3
28	Kinetics of pharmacologic response. , 1982, 16, 143-166.		432
29	Pharmacokinetics and pharmacodynamics of the antiarrhythmic compound MD750819 in dogs with experimentally induced arrhythmias. Journal of Pharmacokinetics and Pharmacodynamics, 1982, 10, 283-296.	0.6	3
30	Pharmacokinetics of pancuronium in man: A linear system. European Journal of Clinical Pharmacology, 1982, 23, 369-372.	0.8	7
31	Pharmacokinetics and pharmacodynamics of thiopentone.. Anaesthesia, 1982, 37, 398-404.	1.8	84
32	Kinetics of drug effect by distributed lags analysis: An application to cocaine. Clinical Pharmacology and Therapeutics, 1982, 31, 775-782.	2.3	21
33	Apple II program to simulate the response " Time profile of non-depolarising muscle relaxants. Computers in Biology and Medicine, 1983, 13, 171-174.	3.9	1
34	Model determination for use in automated control of drug dosages: application to d-tubocurarine. Medical and Biological Engineering and Computing, 1983, 21, 119-127.	1.6	8
35	Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 323-335.	0.6	27
36	Application of effect-compartment model to bumetanide-indomethacin interaction in dogs. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 355-368.	0.6	5
37	Kinetics of d-tubocurarine disposition and pharmacologic response in rats. Journal of Pharmacokinetics and Pharmacodynamics, 1983, 11, 47-61.	0.6	4

#	ARTICLE	IF	CITATIONS
38	Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man. <i>European Journal of Clinical Pharmacology</i> , 1983, 24, 407-413.	0.8	4
39	A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepines. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1983, 7, 629-635.	2.5	33
40	Labetalol disposition and concentration-effect relationships during pregnancy.. <i>British Journal of Clinical Pharmacology</i> , 1983, 15, 465-470.	1.1	45
41	Doxazosin, an alpha 1-renoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.. <i>British Journal of Clinical Pharmacology</i> , 1983, 15, 719-725.	1.1	84
42	Relationship Between Gallamine Plasma Concentration and Neuromuscular Paralysis in Surgical Patients. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 243-251.	1.0	9
43	Pharmacokinetics in Renal Failure. <i>Anaesthesia and Intensive Care</i> , 1983, 11, 350-360.	0.2	6
44	Integrated Pharmacokinetic-Dynamic Modeling of Drugs Acting on the CNS. <i>Drug Metabolism Reviews</i> , 1984, 15, 383-400.	1.5	18
45	Pharmacodynamic modeling of thiopental anesthesia. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1984, 12, 223-240.	0.6	93
46	Pharmacokinetic-pharmacodynamic modelling and simulation using the electrical circuit simulation program spice2. <i>Biopharmaceutics and Drug Disposition</i> , 1984, 5, 315-333.	1.1	10
47	Pharmacokinetic and pharmacodynamic modelling with pancuronium. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 243-250.	0.8	19
48	Prediction of response to theophylline in chronic bronchitis.. <i>British Journal of Clinical Pharmacology</i> , 1984, 17, 1-8.	1.1	26
49	Relation between time courses of pharmacological effects and of plasma levels of camazepam and its active metabolites in rats.. <i>Journal of Pharmacobio-dynamics</i> , 1985, 8, 597-606.	0.5	12
50	A pharmacokinetic model for simulating drug concentrations in tissues or fluids and its application to antibiotics.. <i>Chemical and Pharmaceutical Bulletin</i> , 1985, 33, 2974-2982.	0.6	7
51	Accelerated onset of pancuronium with divided doses. <i>Canadian Anaesthetists' Society Journal</i> , 1985, 32, 1-4.	0.5	21
52	Pharmacokinetics and clinical anaesthesia. <i>Canadian Anaesthetists' Society Journal</i> , 1985, 32, S12-S15.	0.5	1
53	Integrated Pharmacokinetics and Pharmacodynamics of Atropine in Healthy Humans I: Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 703-710.	1.6	47
54	Integrated Pharmacokinetics and Pharmacodynamics of Atropine in Healthy Humans II: Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 711-717.	1.6	28
55	The relationship between serum concentrations and central nervous system actions of metoprolol.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1985, 48, 101-106.	0.9	12

#	ARTICLE	IF	CITATIONS
56	Feedback Control Methods for Drug Dosage Optimisation. <i>Clinical Pharmacokinetics</i> , 1985, 10, 457-476.	1.6	62
57	Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects.. <i>British Journal of Clinical Pharmacology</i> , 1985, 20, 55S-61S.	1.1	26
58	The graded and quantal nature of opioid analgesia in the rat tailflick assay. <i>Brain Research</i> , 1985, 331, 327-336.	1.1	17
59	The pharmacodynamic response of the basal skin potential to quinidine gluconate. <i>Life Sciences</i> , 1986, 38, 417-424.	2.0	0
60	Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201â€“403 by an integrated pharmacokineticâ€“pharmacodynamic model.. <i>British Journal of Clinical Pharmacology</i> , 1986, 22, 1-13.	1.1	14
61	A Novel Pharmacokinetic Method for Analysis of Placental Transfer of Latamoxef in Humans. <i>Clinical Pharmacokinetics</i> , 1986, 11, 154-163.	1.6	6
62	Kinetics of drug action: An overview. <i>Journal of Allergy and Clinical Immunology</i> , 1986, 78, 754-761.	1.5	24
63	A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. <i>Journal of Pharmacological Methods</i> , 1986, 16, 277-296.	0.7	20
64	Trimoprostil Plasma Concentrationâ€“Gastric Acid Inhibition Relationships in Duodenal Ulcer Patients. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 48-54.	1.0	2
65	Pharmacokinetic and Pharmacodynamic Modeling of Cibenzoline Plasma Concentrations and Antiarrhythmic Effect. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 336-345.	1.0	7
66	Modeling the pharmacokinetics and pharmacodynamics of trimazosin. <i>Biopharmaceutics and Drug Disposition</i> , 1986, 7, 373-388.	1.1	3
67	Computer applications in intravenous anaesthetic administration. <i>Journal of Clinical Monitoring and Computing</i> , 1986, 3, 269-278.	0.3	1
68	Administration of Atracurium by Infusion for Long Surgical Procedures. <i>British Journal of Anaesthesia</i> , 1986, 58, 56S-59S.	1.5	6
69	Attenuation of Response to Mental Stress in Patients With Essential Tremor Treated With Metoprolol. <i>Archives of Neurology</i> , 1986, 43, 687-689.	4.9	7
70	Perindopril, A New Angiotensin Converting Enzyme Inhibitorâ€“Clinical Pharmacological Studies in Healthy Subjects. <i>Clinical and Experimental Hypertension</i> , 1987, 9, 361-364.	0.3	4
71	Controversy II: Bioequivalence as an Indicator of Therapeutic Equivalence: Modeling the Theoretic Influence of Bioinequivalence on Singleâ€“Dose Drug Effect. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 342-345.	1.0	8
72	Pharmacokinetic and pharmacodynamic studies of piretanide in rabbits. I. Effect of different hydrated conditions.. <i>Journal of Pharmacobio-dynamics</i> , 1987, 10, 356-363.	0.5	11
73	Intravenous Anaesthetic Agents. <i>Clinical Pharmacokinetics</i> , 1987, 12, 79-110.	1.6	40

#	ARTICLE	IF	CITATIONS
74	Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: An appraisal of study methodology. <i>Cardiovascular Drugs and Therapy</i> , 1987, 1, 183-189.	1.3	5
75	Models for the Pharmacokinetics and Pharmacodynamics of Insulin in Alloxan-Induced Diabetic Dogs. <i>Journal of Pharmaceutical Sciences</i> , 1987, 76, 295-299.	1.6	12
76	Study of doxorubicin photodegradation in plasma, urine and cell culture medium by HPLC. <i>Biomedical Chromatography</i> , 1987, 2, 242-244.	0.8	12
77	Pharmacokinetic/pharmacodynamic modeling: What it is!. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 545-553.	0.6	21
78	Commentary to pharmacokinetic/pharmacodynamic modeling: What it is!. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 553-555.	0.6	4
79	Kinetics of ajmaline disposition and pharmacologic response in beagle dogs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 39-55.	0.6	8
80	Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1987, 12, 41-48.	0.6	3
81	Kinetic-effect models and their applications. <i>Pharmaceutical Research</i> , 1987, 04, 86-91.	1.7	9
82	Pharmacodynamics of zoxazolamine and chlorzoxazone in rats. <i>Pharmaceutical Research</i> , 1988, 05, 401-407.	1.7	9
83	Pharmacodynamics of Chlorzoxazone in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1988, 77, 383-386.	1.6	4
84	Simulating the time-course of clinical paralysis. <i>Journal of Clinical Monitoring and Computing</i> , 1988, 5, 201-205.	0.3	0
85	Onset of action of relaxants. <i>Canadian Journal of Anaesthesia</i> , 1988, 35, S52-S58.	0.7	151
86	Comparison of the antihypertensive effects of celiprolol and acebutolol. <i>European Journal of Clinical Pharmacology</i> , 1988, 34, 125-128.	0.8	4
87	Extracorporeal techniques in the treatment of exogenous intoxications. <i>Kidney International</i> , 1988, 33, 735-754.	2.6	84
88	Kinetics of drug activities as influenced by their physico-chemical properties: Antibacterial effects of alkylating 2-furylethylenes. <i>Journal of Theoretical Biology</i> , 1988, 131, 115-134.	0.8	24
89	Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to <i>Pseudomonas aeruginosa</i> . <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 355-375.	0.6	73
90	Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: An overview. , 1988, 38, 1-52.		83
91	Initial blood pressure as a predictor of the response to antihypertensive therapy.. <i>British Journal of Clinical Pharmacology</i> , 1988, 26, 715-720.	1.1	26

#	ARTICLE	IF	CITATIONS
92	Drug distribution in the body. <i>General Pharmacology</i> , 1988, 19, 357-360.	0.7	4
93	The Efficacy of Rifampicin against <i>Staphylococcus aureus</i> in Vitro and in an Experimental Infection in Normal and Granulocytopenic Mice. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 649-656.	1.5	6
94	Basic Concepts in Pharmacodynamic Modeling. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 388-394.	1.0	37
95	The Effect of $\alpha$ -Blockers on Mental Performance on Older Hypertensive Patients. <i>Archives of Internal Medicine</i> , 1988, 148, 779.	4.3	58
96	The Metabolism of 5-(4-Acetamidophenyl)Pyrazin-2(1H)-One in Rat, Dog and Cynomolgus Monkey. <i>Xenobiotica</i> , 1988, 18, 1373-1387.	0.5	3
97	Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. <i>Xenobiotica</i> , 1988, 18, 123-129.	0.5	2
98	Importance of Oral Dosing Rate on the Hemodynamic and Pharmacokinetic Profile on Nilvadipine. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 1001-1007.	1.0	4
99	Combined Pharmacokinetic/ Pharmacodynamic (PK/PD) Modeling. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 769-771.	1.0	14
100	Pharmacodynamics of Procainamide in Patients With Ventricular Tachyarrhythmias. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 984-989.	1.0	4
101	Pharmacokinetic and pharmacodynamic studies of piretanide in rabbits. IV. Effects of piretanide on the proximal tubules and the loop of henle under a hydrated condition.. <i>Journal of Pharmacobio-dynamics</i> , 1988, 11, 794-800.	0.5	1
102	Kinetic analysis of the positive inotropic action(PIA) of ouabain in isolated perfused rabbit heart. Slow onset of PIA and slow binding to Na <sup>+</sup> , K <sup>+</sup> -adenosine triphosphatase.. <i>Journal of Pharmacobio-dynamics</i> , 1988, 11, 533-540.	0.5	8
103	Comparison of in Vivo and in Vitro Activities of Antibiotics with Different Modes of Action against a Tolerant and a Non-tolerant <i>Staphylococcus aureus</i> Strain. <i>Scandinavian Journal of Infectious Diseases</i> , 1989, 21, 95-101.	1.5	7
104	Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: Relationship of pharmacokinetics and pharmacodynamics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 551-570.	0.6	7
105	Second generation model for prednisolone pharmacodynamics in the rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 209-227.	0.6	40
106	Pharmacodynamic modeling of digoxin-induced bradycardia. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 89-107.	0.6	3
107	Placental transfer and tissue distribution of thiopental in the pregnant rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 425-440.	0.6	5
108	A comparison of parametric with semiparametric analysis of the concentration versus effect relationship of metocurine in dogs and pigs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 291-304.	0.6	15
109	Clockwise hysteresis or proteresis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 401-402.	0.6	26

#	ARTICLE	IF	CITATIONS
110	Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1989, 14, 145-151.	0.6	15
111	Use of the median EEG frequency and pharmacokinetics in determining depth of anaesthesia. <i>Bailliere's Clinical Anaesthesiology</i> , 1989, 3, 603-621.	0.2	12
112	Effect of Plasma Protein Binding on Kinetics of PN 200â€10 in the Isolated Perfused Rat Heart. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1989, 65, 258-264.	0.0	4
113	The delivery of peptides. <i>Journal of Pharmaceutical Sciences</i> , 1989, 78, 883-892.	1.6	9
114	Current models in pharmacokinetics: Applications in veterinary pharmacology. <i>Veterinary Research Communications</i> , 1989, 13, 141-157.	0.6	6
115	Alteration by burn injury of the pharmacokinetics and pharmacodynamics of cimetidine in children. <i>European Journal of Clinical Pharmacology</i> , 1989, 36, 361-367.	0.8	18
116	Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 616-628.	2.3	73
117	Relation of disposition kinetics to pharmacological effect of intravenous administration of chlorzoxazone in rats.. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 367-373.	0.5	6
118	Comparison of the pharmacodynamic effects of intravenous and oral propafenone. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 245-254.	2.3	21
119	Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 459-481.	0.6	36
120	Estimating the rate of thiopental blood-brain equilibration using pseudo steady state serum concentrations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 175-187.	0.6	10
121	Relationship between train-of-four ratio and first-twitch depression during neuromuscular blockade: A pharmacokinetic/dynamic explanation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 335-346.	0.6	8
122	Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines I: Lorazepam. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1990, 18, 89-102.	0.6	37
123	Factors influencing the responses to calcium antagonists in elderly patients with hypertension and ischaemic heart disease. <i>Experimental Gerontology</i> , 1990, 25, 375-381.	1.2	9
124	Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam. <i>Pharmaceutical Research</i> , 1990, 07, 570-576.	1.7	13
125	A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade. <i>Journal of Clinical Monitoring and Computing</i> , 1990, 6, 24-38.	0.6	1
126	The use of kinetic-dynamic interactions in the evaluation of drugs. <i>Psychopharmacology</i> , 1990, 100, 433-450.	1.5	53
127	Correlation Between Pharmacokinetics and Pharmacologic Effects of a New Imidazole Thromboxane Synthetase Inhibitor. <i>Journal of Pharmaceutical Sciences</i> , 1990, 79, 295-300.	1.6	7



#	ARTICLE	IF	CITATIONS
128	Neuromuscular Sensitivity to Atracurium in Humans. <i>Anaesthesia and Intensive Care</i> , 1990, 18, 62-68.	0.2	6
129	Issues in Contemporary Drug Delivery. <i>Journal of Pharmacy Technology</i> , 1990, 6, 200-211.	0.5	1
130	Concentration-effect analysis of antihypertensive drug responses.. <i>Hypertension</i> , 1990, 16, 12-18.	1.3	30
131	PHARMACODYNAMICS OF ATRACURIUM DURING PROPOFOL, THIOPENTONE AND OPIOID ANAESTHESIA. <i>British Journal of Anaesthesia</i> , 1990, 65, 675-683.	1.5	5
132	Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 1869-1874.	1.4	67
133	AntibactERial Activity of Four Cephalosporins in an ExpERimental Infection in Relation to In Vitro Effect and Pharmacokinetics. <i>Journal of Infectious Diseases</i> , 1990, 162, 717-722.	1.9	30
134	Pharmacokinetic and pharmacodynamic aspects of polypeptide delivery. <i>Journal of Controlled Release</i> , 1990, 11, 343-356.	4.8	32
135	Corticosteroid Pharmacodynamics: Models for a Broad Array of Receptorâ€Mediated Pharmacologic Effects. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 303-310.	1.0	25
136	The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives*. <i>Fundamental and Clinical Pharmacology</i> , 1990, 4, 103s-115s.	1.0	4
137	Compartmental mean residence time in a mammillary model with an effect compartment after intravenous or oral administration. <i>Journal of Biomedical Engineering</i> , 1990, 12, 523-526.	0.7	1
138	Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. <i>British Journal of Pharmacology</i> , 1990, 101, 843-846.	2.7	10
139	Phannacokineticâ€pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. <i>British Journal of Pharmacology</i> , 1990, 99, 53-58.	2.7	13
140	Pharmacodynamic modeling of lymphocytopenia and whole blood lymphocyte cultures in prednisolone-treated individuals. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 374-386.	2.1	11
141	Hearing impairment related to plasma quinine concentration in healthy volunteers.. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 409-412.	1.1	29
142	Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.. <i>British Journal of Clinical Pharmacology</i> , 1991, 31, 671-676.	1.1	4
143	Adaptive feedback-controlled infusion versus repetitive injections of vecuronium in patients during isoflurane anesthesia. <i>Journal of Clinical Anesthesia</i> , 1991, 3, 181-185.	0.7	7
144	Pharmacodynamic Modelling. <i>Clinical Pharmacokinetics</i> , 1991, 20, 91-98.	1.6	31
145	Biologically Based Pharmacodynamic Models: Tools for Toxicological Research and Risk Assessment. <i>Annual Review of Pharmacology and Toxicology</i> , 1991, 31, 503-523.	4.2	79

#	ARTICLE	IF	CITATIONS
146	Chaos and illusion. Trends in Pharmacological Sciences, 1991, 12, 379-383.	4.0	21
147	Chronotherapeutics.. Annals of the New York Academy of Sciences, 1991, 618, 116-122.	1.8	3
148	Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605). Pharmaceutical Research, 1991, 08, 1505-1510.	1.7	15
149	Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203922. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 287-309.	0.6	16
150	Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 617-634.	0.6	20
151	Semiparametric analysis of non-steady-state pharmacodynamic data. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 691-712.	0.6	26
152	A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 537-552.	0.6	58
153	Losartan (DuP 753), An Orally Active Nonpeptide Angiotensin II Receptor Antagonist. Cardiovascular Drug Reviews, 1991, 9, 317-339.	4.4	49
154	Clinical pharmacokinetics of anaesthetic drugs: an overview. Bailliere's Clinical Anaesthesiology, 1991, 5, 479-488.	0.2	0
155	Pharmacokinetic and pharmacodynamic principles. Bailliere's Clinical Anaesthesiology, 1991, 5, 489-511.	0.2	0
156	Pharmacokinetics of muscle relaxants and cholinesterase inhibitors. Bailliere's Clinical Anaesthesiology, 1991, 5, 567-591.	0.2	0
157	A simple analytical solution to the three-compartment pharmacokinetic model suitable for computer-controlled infusion pumps. IEEE Transactions on Biomedical Engineering, 1991, 38, 522-525.	2.5	52
158	Model-based adaptive closed-loop feedback control of atracurium-induced neuromuscular blockade. Acta Anaesthesiologica Scandinavica, 1991, 35, 420-423.	0.7	30
159	Relationship between Red Blood Cell Potassium and Plasma Digitoxin Concentrations in Intoxicated Patients. Basic and Clinical Pharmacology and Toxicology, 1991, 68, 237-242.	0.0	2
160	Relationship between Skin Fluorescence and Blood Flow in Normal and in Chronically Ischemic Subjects Dosed with Fluorescein. Journal of Pharmaceutical Sciences, 1991, 80, 632-637.	1.6	2
161	Use of a pharmacokinetic-dynamic model for the automatic feedback control of atracurium. European Journal of Clinical Pharmacology, 1991, 40, 293-296.	0.8	25
162	RELATIONSHIP OF THE TRAIN-OF-FOUR RATIO TO PLASMA ATRACURIUM CONCENTRATION. British Journal of Anaesthesia, 1992, 69, 274-280.	1.5	2
163	DEPENDENCE OF THE NEUROMUSCULAR BLOCKING EFFECT OF ATRACURIUM UPON ITS DISPOSITION. British Journal of Anaesthesia, 1992, 68, 555-561.	1.5	7

#	ARTICLE	IF	CITATIONS
164	Dosage Regimen Design: Pharmacodynamic Considerations. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 597-602.	1.0	9
165	Generalised predictive control (GPC) in the operating theatre. <i>IEE Proceedings D: Control Theory and Applications</i> , 1992, 139, 404.	0.4	23
166	Population Pharmacokinetics/Dynamics*. <i>Annual Review of Pharmacology and Toxicology</i> , 1992, 32, 185-209.	4.2	294
167	Separation of the Pharmacokinetic/Pharmacodynamic Properties of Oral and IV Adinazolam Mesylate and N-Desmethyadinazolam Mesylate in Healthy Volunteers. <i>Drug Investigation</i> , 1992, 4, 155-165.	0.6	7
168	Antihypertensive drugs: Individualized analysis and clinical relevance of kinetic-dynamic relationships. <i>Journal of Clinical Pharmacology</i> , 1992, 53, 67-79.		12
169	Phencyclidine and auditory sensory gating in the hippocampus of the rat. <i>Neuropharmacology</i> , 1992, 31, 1041-1048.	2.0	83
170	Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 655-61.	0.8	20
171	Pharmacodynamic modeling of their in vitro vasodilating effects of organic mononitrates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 227-251.	0.6	9
172	Application of semilinear canonical correlation to the measurement of opioid drug effect. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 611-635.	0.6	27
173	Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1992, 20, 147-169.	0.6	223
174	Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 51-55.	0.8	18
175	Educational computer simulation of malignant hyperthermia. <i>Journal of Clinical Monitoring and Computing</i> , 1992, 8, 201-208.	0.6	7
176	Rapid chiral separation of metoprolol in plasma-application to the pharmacokinetics/pharmacodynamics of metoprolol enantiomers in the conscious goat. <i>Biomedical Chromatography</i> , 1992, 6, 99-105.	0.8	8
177	Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease. <i>Movement Disorders</i> , 1992, 7, 244-248.	2.2	17
178	Pharmacokinetic-Pharmacodynamic Modeling: Time-Dependent Protein Binding—An Alternative Interpretation of Clockwise and Counterclockwise Hysteresis. <i>Journal of Pharmaceutical Sciences</i> , 1992, 81, 232-236.	1.6	12
179	Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 177-182.	0.8	6
180	Pharmacokinetic-pharmacodynamic modeling of caffeine: Tolerance to pressor effects. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 6-14.	2.3	86
181	Disposition and efficacy of alcuronium in young children undergoing elective surgery. <i>Paediatric Anaesthesia</i> , 1993, 3, 235-238.	0.6	1

#	ARTICLE	IF	CITATIONS
182	The isolated heart-lung preparation in the cat an in situ model to study the role of the lungs in the disposition of drugs. <i>Journal of Pharmacological and Toxicological Methods</i> , 1993, 29, 147-156.	0.3	4
183	Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study. <i>Pharmaceutical Research</i> , 1993, 10, 889-894.	1.7	5
184	Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glycerol dinitrate upon blood pressure in healthy volunteers. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 515-532.	0.6	3
185	A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 309-321.	0.6	20
186	Comparison of four basic models of indirect pharmacodynamic responses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993, 21, 457-478.	0.6	699
187	Pharmacokinetic and pharmacodynamic data and models in clinical trials. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1993, 18, 61-76.	0.6	33
188	Râ€verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 93-98.	1.1	9
189	Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 1-9.	1.1	11
190	Importance of Early Blood Sampling on Vecuronium Pharmacokinetic and Pharmacodynamic Parameters. <i>Clinical Pharmacokinetics</i> , 1993, 24, 507-518.	1.6	50
191	Pharmacokinetics and Electrophysiological Effects of Intravenous Ajmaline. <i>Clinical Pharmacokinetics</i> , 1993, 25, 408-414.	1.6	27
192	Dataâ€derived safety factors for the evaluation of food additives and environmental contaminants. <i>Food Additives and Contaminants</i> , 1993, 10, 275-305.	2.0	270
193	Activity of Erythromycin and Clindamycin in an Experimental <i>Staphylococcus aureus</i> Infection in Normal and Granulocytopenic Mice. <i>Scandinavian Journal of Infectious Diseases</i> , 1993, 25, 123-132.	1.5	6
194	Prediction and Optimisation of the Antihypertensive Response to Nifedipine. <i>Blood Pressure</i> , 1994, 3, 303-308.	0.7	6
195	Pharmacokinetic/Pharmacodynamic Consequences of Space Flight. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 684-691.	1.0	16
196	Pharmacokinetic and pharmacodynamic models of antimicrobial drugsIn vitro andIn vivo. <i>Infection</i> , 1994, 22, 377-378.	2.3	2
197	Inhibition of rat splenocyte proliferation with methylprednisolone: in vivo effect of liposomal formulation. <i>Pharmaceutical Research</i> , 1994, 11, 848-854.	1.7	20
198	Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil. <i>Pharmaceutical Research</i> , 1994, 11, 128-135.	1.7	2
199	Comparison of some control strategies for three-compartment PK/PD models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1994, 22, 525-550.	0.6	14

#	ARTICLE	IF	CITATIONS
200	Sensitivities of different muscles to relaxant drugs. Bailliere's Clinical Anaesthesiology, 1994, 8, 369-394.	0.2	4
201	Pharmacokinetic-Pharmacodynamic modelling of meperidine in goats (II): modelling. Journal of Veterinary Pharmacology and Therapeutics, 1994, 17, 127-134.	0.6	8
202	Vecuronium Pharmacokinetic-Pharmacodynamic Modelling With and Without a Receptor Concentration in the Effect Compartment in Anaesthetised Patients. Drug Investigation, 1994, 7, 74-83.	0.6	7
203	Concentration-Effect Analysis of Antihypertensive Drug Response. Clinical Pharmacokinetics, 1994, 26, 472-485.	1.6	12
204	Kinetic Analysis of Neuromuscular Blockade. I. Relationship between Twitch Depression and Stimulation Frequency after d-Tubocurarine Administration.. Biological and Pharmaceutical Bulletin, 1994, 17, 1083-1088.	0.6	5
205	Development of a Closed Loop System for Neuromuscular Blocking Agents Given in Intensive Care. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1994, 27, 181-183.	0.4	2
206	The Maximum Depth of an Atracurium Neuromuscular Block Antagonized by Edrophonium to Effect Adequate Recovery. Anesthesiology, 1995, 82, 852-858..	1.3	26
207	The Pharmacodynamics and Pharmacokinetics of Alcuronium. Anesthesia and Analgesia, 1995, 81, 1315.	1.1	0
208	Alcuronium. Anesthesia and Analgesia, 1995, 80, 373-377.	1.1	0
209	The Pharmacodynamics and Pharmacokinetics of Alcuronium. Anesthesia and Analgesia, 1995, 81, 1315-1316.	1.1	0
210	Validation of the Alfentanil Canonical Univariate Parameter as a Measure of Opioid Effect on the Electroencephalogram. Anesthesiology, 1995, 83, 747-756..	1.3	43
211	The Pharmacodynamics and Pharmacokinetics of Alcuronium. Anesthesia and Analgesia, 1995, 81, 1315.	1.1	1
212	Measured Context-sensitive Half-times of Remifentanil and Alfentanil. Anesthesiology, 1995, 83, 968-975.	1.3	421
213	The Pharmacodynamics and Pharmacokinetics of Alcuronium. Anesthesia and Analgesia, 1995, 81, 1315-1316.	1.1	0
214	Pharmacokinetic and Pharmacodynamic Studies of Centrally Acting Drugs in Rat: Effect of Pentobarbital and Chlorpromazine on Electroencephalogram in Rat.. Biological and Pharmaceutical Bulletin, 1995, 18, 1094-1103.	0.6	11
215	Alcuronium. Anesthesia and Analgesia, 1995, 80, 373-377.	1.1	7
216	The Pharmacokinetics and Neuromuscular Effects of Rocuronium Bromide in Patients with Liver Disease. Anesthesia and Analgesia, 1995, 80, 754-759.	1.1	5
217	Open loop control of multiple drug effects in anesthesia. IEEE Transactions on Biomedical Engineering, 1995, 42, 666-677.	2.5	12

#	ARTICLE	IF	CITATIONS
218	Neuromuscular blocking drugs in pediatric anesthesia. <i>Seminars in Anesthesia</i> , 1995, 14, 16-25.	0.3	0
219	Compartment Model To Describe Peripheral Arterial-Venous Drug Concentration Gradients with Drug Elimination from the Venous Sampling Compartment. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 370-375.	1.6	16
220	Further notes on physiologic indirect response models*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 238-240.	2.3	17
221	Pharmacokinetic analysis of the time course of effect of atracurium. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 390-397.	2.3	5
222	Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 631-640.	2.3	17
223	Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 533-542.	2.3	61
224	Difference of train-of-four fade induced by nondepolarizing neuromuscular blocking drugs: a theoretical consideration on the underlying mechanisms. <i>Journal of Anesthesia</i> , 1995, 9, 333-337.	0.7	2
225	A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1995, 23, 531-549.	0.6	28
226	A semicompartamental modeling approach for pharmacodynamic data assessment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1995, 23, 307-322.	0.6	3
227	Nitrous oxide produces a biphasic effect on opiate-induced muscle rigidity in the rat. <i>Pharmacology Biochemistry and Behavior</i> , 1995, 50, 351-358.	1.3	2
228	Observability of system state variables as a means to evaluate monitoring techniques. , 0, , .		0
229	The Pharmacokinetics and Neuromuscular Effects of Rocuronium Bromide in Patients with Liver Disease. <i>Anesthesia and Analgesia</i> , 1995, 80, 754-759.	1.1	113
230	Calculation of an effect compartment rate constant using recovery indices obtained with an isolated arm technique. <i>British Journal of Anaesthesia</i> , 1995, 75, 109-112.	1.5	0
231	Structural identifiability and indistinguishability of certain two-compartment models incorporating nonlinear efflux from the peripheral compartment. <i>Mathematical Biosciences</i> , 1995, 125, 61-81.	0.9	6
232	Chapter 13 Enantioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain. <i>Progress in Brain Research</i> , 1995, 106, 123-134.	0.9	60
233	Population Pharmacokinetics: Fundamentals, Methods and Applications. <i>Drug Development and Industrial Pharmacy</i> , 1995, 21, 1115-1141.	0.9	11
234	Pharmacokinetics and Pharmacodynamics of a Second Dose of Atracurium in Anaesthetised Patients. <i>Clinical Drug Investigation</i> , 1995, 9, 98-110.	1.1	7
235	Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 185-191.	2.3	70

#	ARTICLE	IF	CITATIONS
236	AN APPLICATION OF BAYESIAN POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELS TO DOSE RECOMMENDATION. <i>Statistics in Medicine</i> , 1995, 14, 971-986.	0.8	54
237	Chronopharmacokinetics and Chronopharmacodynamics of Dextromethamphetamine in Man. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 1051-1063.	1.0	42
238	Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines. <i>Clinical Pharmacokinetics</i> , 1996, 30, 52-76.	1.6	81
239	Neostigmine Reversal of Vecuronium Neuromuscular Block and the Influence of Renal Failure. <i>Anesthesia and Analgesia</i> , 1996, 82, 134-138.	1.1	2
240	(Almost) Everything You Learned About Pharmacokinetics Was (Somewhat) Wrong!. <i>Anesthesia and Analgesia</i> , 1996, 83, 901-903.	1.1	19
241	Semilinear Canonical Correlation Applied to the Measurement of the Electroencephalographic Effects of Midazolam and Flumazenil Reversal. <i>Anesthesiology</i> , 1996, 84, 510-519.	1.3	17
242	Reduction of Isoflurane Minimal Alveolar Concentration by Remifentanyl. <i>Anesthesiology</i> , 1996, 85, 721-728.	1.3	237
243	Pharmacokinetics and Pharmacodynamics of Cisatracurium in Young and Elderly Adult Patients. <i>Anesthesiology</i> , 1996, 84, 1083-1091.	1.3	91
244	Neostigmine Reversal of Vecuronium Neuromuscular Block and the Influence of Renal Failure. <i>Anesthesia and Analgesia</i> , 1996, 82, 134-138.	1.1	7
245	(Almost) Everything You Learned About Pharmacokinetics Was (Somewhat) Wrong!. <i>Anesthesia and Analgesia</i> , 1996, 83, 901-903.	1.1	36
246	Pharmacokinetic-Pharmacodynamic Analysis of the Electrocardiographic Effects of Terfenadine and Quinidine in Rats.. <i>Biological and Pharmaceutical Bulletin</i> , 1996, 19, 1189-1196.	0.6	19
247	Population Pharmacodynamics: Strategies for Concentration- and Effect-Controlled Clinical Trials. <i>Annals of Pharmacotherapy</i> , 1996, 30, 12-19.	0.9	21
248	Comparative Pharmacodynamics of Eight Calcium Channel Blocking Agents in Japanese Essential Hypertensive Patients.. <i>Biological and Pharmaceutical Bulletin</i> , 1996, 19, 430-437.	0.6	60
249	In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 1-18.	0.6	14
250	An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1996, 24, 45-77.	0.6	26
251	Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data. <i>Pharmaceutical Research</i> , 1996, 13, 1804-1810.	1.7	9
252	Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. <i>European Journal of Clinical Pharmacology</i> , 1996, 51, 59-67.	0.8	30
253	A pharmacokinetic-pharmacodynamic model for a muscle relaxant: atracurium. <i>European Journal of Clinical Pharmacology</i> , 1996, 49, 325-332.	0.8	2



#	ARTICLE	IF	CITATIONS
254	Artificial Neural Networks As a Novel Approach to Integrated Pharmacokinetic-Pharmacodynamic Analysis. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 505-510.	1.6	59
255	Myocardial Pharmacokinetics of Thiopental in Sheep after Short-Term Administration: Relationship to Thiopental-Induced Reductions in Myocardial Contractility. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 863-867.	1.6	9
256	Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. <i>British Journal of Anaesthesia</i> , 1996, 76, 624-628.	1.5	99
257	Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials. <i>Journal of the American Statistical Association</i> , 1997, 92, 1235-1244.	1.8	74
258	Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. <i>British Journal of Anaesthesia</i> , 1997, 78, 690-695.	1.5	45
259	A physiological model of induction of anaesthesia with propofol in sheep. 1. Structure and estimation of variables. <i>British Journal of Anaesthesia</i> , 1997, 79, 497-504.	1.5	63
260	Pharmacokinetics, Pharmacodynamics, and Cardiopulmonary Bypass. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 1997, 1, 99-108.	0.4	1
261	Propofol Anesthesia and Rational Opioid Selection. <i>Anesthesiology</i> , 1997, 87, 1549-1562.	1.3	278
262	Are Plasma Concentration Values Necessary for Pharmacodynamic Modeling of Muscle Relaxants?. <i>Anesthesiology</i> , 1997, 86, 567-575.	1.3	25
263	Pharmacodynamic Modeling of Vecuronium-induced Twitch Depression. <i>Anesthesiology</i> , 1997, 86, 558-566.	1.3	44
264	Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development. <i>Clinical Pharmacokinetics</i> , 1997, 32, 259-267.	1.6	93
265	Pharmacokinetic Optimisation of Opioid Treatment in Acute Pain Therapy. <i>Clinical Pharmacokinetics</i> , 1997, 33, 225-244.	1.6	102
266	Pharmacokinetics and Pharmacodynamics of Sedatives and Analgesics in the Treatment of Agitated Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 1997, 33, 426-453.	1.6	97
267	Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. <i>Biochemical Pharmacology</i> , 1997, 53, 1451-1457.	2.0	29
268	Neuromuscular Blocking Drugs: Onset and Intubation. <i>Journal of Clinical Anesthesia</i> , 1997, 9, 36S-39S.	0.7	33
269	The Train-of-Four Count and Kinetic-Dynamic Modelling. <i>Journal of Clinical Anesthesia</i> , 1997, 9, 40S-44S.	0.7	3
270	Closed-loop stability of pharmacokinetic-pharmacodynamic models. <i>Mathematical Biosciences</i> , 1997, 146, 75-88.	0.9	2
271	Size, Myths and the Clinical Pharmacokinetics of Analgesia in Paediatric Patients. <i>Clinical Pharmacokinetics</i> , 1997, 33, 313-327.	1.6	180



#	ARTICLE	IF	CITATIONS
272	Dose-Related Hemodynamic and Electrocardiographic Effects of the Calcium Promoter BAY y 5959 in the Presence or Absence of Congestive Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1751-1757.	1.2	4
273	Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. <i>Acta Anaesthesiologica Scandinavica</i> , 1997, 41, 888-894.	0.7	28
274	Onset of the neuromuscular block simulated in an anatomical model. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 55-63.	1.1	2
275	Pharmacokineticâ€“Pharmacodynamic Modeling of Mivacurium in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 252-256.	1.6	1
276	A Kinetic Analysis of the Effects of Î²-Phenylethylamine on the Concentrations of Dopamine and Its Metabolites in the Rat Striatum. <i>Journal of Pharmaceutical Sciences</i> , 1997, 86, 487-496.	1.6	10
277	Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia. <i>European Journal of Anaesthesiology</i> , 1997, 14, 488-494.	0.7	6
278	Fuzzy logic for model adaptation of a pharmacokinetic-based closed loop delivery system for pancuronium. <i>Artificial Intelligence in Medicine</i> , 1997, 11, 9-31.	3.8	24
279	Pharmacokinetics as related to anaesthesia. <i>Current Anaesthesia and Critical Care</i> , 1997, 8, 202-206.	0.3	0
280	Simple apparatus for serial blood sampling in rodents permitting simultaneous measurement of locomotor activity as illustrated with cocaine. <i>Journal of Pharmacological and Toxicological Methods</i> , 1997, 37, 9-14.	0.3	9
281	The use of a PID controller to model vecuronium pharmacokinetics and pharmacodynamics during liver transplantation. <i>IEEE Transactions on Biomedical Engineering</i> , 1997, 44, 610-619.	2.5	6
282	New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 313-348.	0.6	3
283	Pharmacokinetic-based minibolus delivery as an alternative to continuous infusion for drugs that exhibit a biophase lag. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 191-208.	0.6	3
284	Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 263-275.	0.6	18
285	The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 39-62.	0.6	20
286	Bioavailability assessment from pharmacologic data: method and clinical evaluation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1997, 25, 349-362.	0.6	0
287	Functional anatomy of full-scale patient simulators. <i>Journal of Clinical Monitoring and Computing</i> , 1997, 13, 317-324.	0.6	46
288	Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys. <i>Pharmaceutical Research</i> , 1997, 14, 329-336.	1.7	2
289	Drug equilibration across the blood-brain barrierâ€“pharmacokinetic considerations based on the microdialysis method. <i>Pharmaceutical Research</i> , 1997, 14, 128-134.	1.7	159

#	ARTICLE	IF	CITATIONS
290	Occlusive mesenteric ischemia and its effects on jejunal intramucosal pH, mesenteric oxygen consumption and oxygen tensions from surfaces of the jejunum in anesthetized pigs. <i>Intensive Care Medicine</i> , 1997, 23, 91-99.	3.9	23
291	Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment. <i>European Journal of Clinical Pharmacology</i> , 1997, 52, 229-234.	0.8	12
292	Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 106-116.	2.3	27
293	A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 11-25.	2.3	74
294	Indirect-response model for the time course of leukopenia with anticancer drugs*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 511-521.	2.3	73
295	Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium. <i>Journal of Clinical Monitoring and Computing</i> , 1998, 14, 329-337.	0.7	4
296	Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. <i>Pharmaceutical Research</i> , 1998, 15, 599-605.	1.7	85
297	Effects of nitro-L-arginine on blood pressure and cardiac index in anesthetized rats: a pharmacokinetic-pharmacodynamic analysis. , 1998, 15, 1063-1068.		3
298	Modeling in anesthesia. , 1998, 14, 57-67.		3
299	Characterization of the dose-dependent time of peak effect in indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 183-206.	0.6	5
300	Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 385-408.	0.6	26
301	Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 559-579.	0.8	43
302	Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1998, 26, 289-317.	0.8	63
303	Myocardial Effect Compartment Modeling of Metoprolol and Sotalol: Importance of Myocardial Subsite Drug Concentration. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 177-182.	1.6	9
304	Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in Pharmacodynamics. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 732-737.	1.6	138
305	Pharmacodynamic aspects of drug administration. Tolerance development. <i>Advanced Drug Delivery Reviews</i> , 1998, 33, 235-240.	6.6	10
306	Pharmacokinetic-pharmacodynamic model for educational simulations. <i>IEEE Transactions on Biomedical Engineering</i> , 1998, 45, 582-590.	2.5	43
307	Hemodynamic effects of the somatostatin analog lanreotide in humans: Placebo-controlled, cross-over dose-ranging echo-doppler study. <i>Hepatology</i> , 1998, 27, 920-925.	3.6	28

#	ARTICLE	IF	CITATIONS
308	Intravenous Infusion Techniques: how to do it and why we should do it. Canadian Journal of Anaesthesia, 1998, 45, R117-R137.	0.7	5
309	Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. British Journal of Clinical Pharmacology, 1998, 45, 229-239.	1.1	178
310	Pharmacokinetic-pharmacodynamic model relating zabciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers. British Journal of Clinical Pharmacology, 1998, 46, 383-393.	1.1	4
311	Expanding clinical applications of population pharmacodynamic modelling. British Journal of Clinical Pharmacology, 1998, 46, 321-333.	1.1	54
312	Human Variability and Noncancer Risk Assessment – An Analysis of the Default Uncertainty Factor. Regulatory Toxicology and Pharmacology, 1998, 27, 3-20.	1.3	227
313	Predicting Effective Drug Concentrations for Individual Patients. Clinical Pharmacokinetics, 1998, 34, 323-333.	1.6	91
314	Chronopharmacokinetics. Clinical Pharmacokinetics, 1998, 35, 83-94.	1.6	141
315	Methodological Issues in Pharmacokinetic-Pharmacodynamic Modelling. Clinical Pharmacokinetics, 1998, 35, 151-166.	1.6	42
316	Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam. European Journal of Pharmacology, 1998, 346, 131-144.	1.7	14
317	Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Intrathecal Neostigmine Methylsulfate in Humans. Anesthesiology, 1998, 89, 1074-1088.	1.3	47
318	Formulation-dependent Brain and Lung Distribution Kinetics of Propofol in Rats. Anesthesiology, 1998, 89, 678-685..	1.3	48
319	Awakening Propofol Concentration with and without Blood-Effect Site Equilibration after Short-term and Long-term Administration of Propofol and Fentanyl Anesthesia. Anesthesiology, 1998, 88, 928-934.	1.3	38
320	Automation in anesthesia. , 1999, , .		6
321	Effect-site modelling of propofol using auditory evoked potentials. British Journal of Anaesthesia, 1999, 82, 333-339.	1.5	54
322	Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers. British Journal of Clinical Pharmacology, 1999, 48, 801-810.	1.1	6
323	Midazolam effects on prepulse inhibition of the acoustic blink reflex. British Journal of Clinical Pharmacology, 1999, 47, 421-426.	1.1	31
324	A pharmacodynamic and pharmacokinetic study with vedaprofen in an equine model of acute nonimmune inflammation. Journal of Veterinary Pharmacology and Therapeutics, 1999, 22, 96-106.	0.6	31
325	Cocaine and alcohol interactions in the rat: Effect on cocaine pharmacokinetics and pharmacodynamics. Journal of Pharmaceutical Sciences, 1999, 88, 459-467.	1.6	24

#	ARTICLE	IF	CITATIONS
326	Influence of arteriovenous sampling on remifentanyl pharmacokinetics and pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 511-518.	2.3	34
327	Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: a novel pharmacokinetic-pharmacodynamic model. <i>Pharmaceutical Research</i> , 1999, 16, 123-129.	1.7	6
328	Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. , 1999, 16, 176-185.		275
329	Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 173-190.	0.6	11
330	Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 301-323.	0.6	29
331	Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 66, 140-151.	2.3	29
332	Basic pharmacodynamic models for agents that alter production of natural cells. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 467-489.	0.8	76
333	Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999, 27, 491-512.	0.8	8
334	Chemical substance kinetics in the case of chronobiological variations of elimination rate. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1999, 24, 293-297.	0.6	0
335	The new relaxants: are they worth it?. <i>Canadian Journal of Anaesthesia</i> , 1999, 46, R88-R100.	0.7	6
336	Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. , 1999, 20, 101-106.		10
337	Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. , 1999, 20, 59-68.		15
339	Clinical Pharmacokinetics of Cisatracurium Besilate. <i>Clinical Pharmacokinetics</i> , 1999, 36, 27-40.	1.6	80
340	Clinical Pharmacokinetics of the Newer Neuromuscular Blocking Drugs. <i>Clinical Pharmacokinetics</i> , 1999, 36, 169-189.	1.6	54
341	Rapacuronium Bromide. <i>Drugs</i> , 1999, 58, 887-918.	4.9	16
342	Pharmacokinetics and Pharmacokinetic-Dynamic Relationship Between Rapacuronium (Org 9487) and Its 3-Desacetyl Metabolite (Org 9488). <i>Anesthesia and Analgesia</i> , 1999, 88, 640-647.	1.1	29
343	The Dynamic Relationship between End-tidal Sevoflurane and Isoflurane Concentrations and Bispectral Index and Spectral Edge Frequency of the Electroencephalogram. <i>Anesthesiology</i> , 1999, 90, 1345-1353.	1.3	147
344	Pharmacokinetics and Pharmacokinetic-Dynamic Relationship Between Rapacuronium (Org 9487) and Its 3-Desacetyl Metabolite (Org 9488). <i>Anesthesia and Analgesia</i> , 1999, 88, 640-647.	1.1	42

#	ARTICLE	IF	CITATIONS
345	The Influence of Age on Propofol Pharmacodynamics. <i>Anesthesiology</i> , 1999, 90, 1502-1516..	1.3	1,036
346	Pharmacokinetics and Pharmacodynamics following Intravenous Doses of Azimilide Dihydrochloride. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 1263-1271.	1.0	9
347	Speed of Onset and Offset and Mechanisms of Ventilatory Depression from Sevoflurane. <i>Anesthesiology</i> , 1999, 90, 1119-1128.	1.3	9
348	The Influence of Renal Function on the Pharmacokinetics and Pharmacodynamics and Simulated Time Course of Doxacurium. <i>Anesthesia and Analgesia</i> , 1999, 89, 786.	1.1	7
349	The Influence of Renal Function on the Pharmacokinetics and Pharmacodynamics and Simulated Time Course of Doxacurium. <i>Anesthesia and Analgesia</i> , 1999, 89, 786.	1.1	7
350	Targeting Effect Compartment or Central Compartment Concentration of Propofol. <i>Anesthesiology</i> , 1999, 90, 92-97.	1.3	115
351	Perioperative Pharmacodynamics of Acetaminophen Analgesia in Children. <i>Anesthesiology</i> , 1999, 90, 411-421.	1.3	170
352	Pharmacokinetic Modeling of M6G Formation after Oral Administration of Morphine in Healthy Volunteers. <i>Anesthesiology</i> , 1999, 90, 1026-1038.	1.3	52
353	Fundamentals of Population Modelling Opportunities for Hospital Pharmacy Practice. <i>Journal of Pharmacy Practice and Research</i> , 1999, 29, 88-91.	0.2	9
354	Bioavailability Assessment of Disopyramide Using Pharmacokinetic-Pharmacodynamic(PK-PD) Modeling in the Rat.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 1363-1369.	0.6	6
356	Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. <i>Critical Care Medicine</i> , 2000, 28, 2750-2757.	0.4	37
357	Post-injection delays in experimental chambers, but not in home cages, produced both sensitization and tolerance of operant behaviour to midazolam: relation to pharmacokinetics. <i>Behavioural Pharmacology</i> , 2000, 11, 133-142.	0.8	3
358	Sex Differences in Morphine Analgesia. <i>Anesthesiology</i> , 2000, 93, 1245-1254.	1.3	367
359	Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 908-917.	1.0	20
360	Pk-fit: A Pharmacokinetic/Pharmacodynamic and Statistical Data Analysis Software. <i>Journal of Biomedical Informatics</i> , 2000, 33, 315-329.	0.7	28
361	Pharmacokinetic studies of neuromuscular blocking agents: Good Clinical Research Practice (GCRP). <i>Acta Anaesthesiologica Scandinavica</i> , 2000, 44, 1169-1190.	0.7	44
362	Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels. <i>British Journal of Pharmacology</i> , 2000, 130, 1037-1044.	2.7	10
363	The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. <i>British Journal of Pharmacology</i> , 2000, 131, 756-760.	2.7	75

#	ARTICLE	IF	CITATIONS
364	On the use of partial AUC as an early exposure metric. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 10, 91-95.	1.9	8
365	Pharmacokinetic-Pharmacodynamic Modeling. <i>Archives of Medical Research</i> , 2000, 31, 539-545.	1.5	56
366	The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment. , 2000, 88, 33-58.		20
367	Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentrationâ€“effect relations: acute tolerance. <i>European Journal of Pharmacology</i> , 2000, 398, 225-238.	1.7	25
368	Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. <i>Pharmaceutical Research</i> , 2000, 17, 77-84.	1.7	46
369	Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 18-27.	2.3	9
370	A pharmacodynamic Markov mixed-effect model for the effect of temazepam on sleep. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 175-188.	2.3	49
371	Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats—a microdialysis study. <i>Pharmaceutical Research</i> , 2000, 17, 1220-1227.	1.7	90
372	Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2000, 25, 49-58.	0.6	68
373	Comparative Pharmacodynamic Analysis of Q-T Interval Prolongation Induced by the Macrolides Clarithromycin, Roxithromycin, and Azithromycin in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2630-2637.	1.4	66
374	Importance of Î²2Adrenergic Receptor Genotype, Gender and Race on Albuterol-evoked Bronchodilation in Asthmatics. <i>Pulmonary Pharmacology and Therapeutics</i> , 2000, 13, 127-134.	1.1	29
375	Morphine-6-Glucuronide. <i>Clinical Pharmacokinetics</i> , 2001, 40, 485-499.	1.6	108
376	Utilisation of Pharmacokinetic- Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making. <i>Clinical Pharmacokinetics</i> , 2001, 40, 883-892.	1.6	60
377	Pharmacokineticâ€“pharmacodynamic modeling in anesthesia. <i>International Congress Series</i> , 2001, 1220, 89-97.	0.2	2
378	Medication non-compliance. <i>International Congress Series</i> , 2001, 1220, 125-133.	0.2	7
379	The electroencephalogram (EEG) and clinical measures of opioid potency: defining the EEG-clinical potency relationship (â€“fingerprintâ€™) with application to remifentanil. <i>Pharmaceutical Medicine</i> , 2001, 15, 11-19.	0.4	14
380	From SIVA to ISAP!â€“A Logical Evolution. <i>Anesthesia and Analgesia</i> , 2001, 92, 1-2.	1.1	5
381	Recirculatory Pharmacokinetics and Pharmacodynamics of Rocuronium in Patients. <i>Anesthesiology</i> , 2001, 94, 47-55.	1.3	56

#	ARTICLE	IF	CITATIONS
382	Predictability of Processed Electroencephalography Effects on the Basis of Pharmacokinetic-Pharmacodynamic Modeling during Repeated Propofol Infusions in Patients with Extradural Analgesia. <i>Anesthesiology</i> , 2001, 95, 607-615.	1.3	30
383	A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium. <i>European Journal of Anaesthesiology</i> , 2001, 18, 83-89.	0.7	1
384	Predictors of onset and offset of drug effect. <i>European Journal of Anaesthesiology</i> , 2001, 18, 26-31.	0.7	4
385	Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic-Dynamic Approach. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 621-629.	1.0	56
386	A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium. <i>European Journal of Anaesthesiology</i> , 2001, 18, 83-89.	0.7	0
387	Predictors of onset and offset of drug effect. <i>European Journal of Anaesthesiology</i> , 2001, 18, 26-31.	0.7	0
388	A Comparative Pharmacodynamic Study of the Arrhythmogenicity of Antidepressants, Fluvoxamine and Imipramine, in Guinea Pigs.. <i>Biological and Pharmaceutical Bulletin</i> , 2001, 24, 550-554.	0.6	12
389	Pharmacokinetic-Pharmacodynamic Modeling of Atracurium in Intensive Care Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 44-50.	1.0	10
390	Brain microdialysis and PK/PD correlation of pregabalin in rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2001, 26, 123-128.	0.6	40
391	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 35-43.	1.1	14
392	Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 25-33.	1.1	13
393	Estimation of absorption rate of $\beta$ -human atrial natriuretic peptide from the plasma profile and diuretic effect after intranasal administration to rats. <i>Biopharmaceutics and Drug Disposition</i> , 2001, 22, 137-146.	1.1	5
394	Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2001, 28, 7-25.	0.8	16
395	Pharmacodynamic modeling of time-dependent transduction systems. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 210-216.	2.3	125
396	Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats- $\beta$ -pharmacokinetic/pharmacodynamic modelling. <i>British Journal of Pharmacology</i> , 2001, 134, 1796-1804.	2.7	91
397	Simultaneous fitting of $\alpha$ - and $\beta$ -bupropfen plasma concentrations after oral administration of the racemate. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 387-398.	1.1	1
398	Approaches to pharmacokinetic/pharmacodynamic modeling during pregnancy. <i>Seminars in Perinatology</i> , 2001, 25, 124-132.	1.1	8
399	Modeling and closed-loop control of hypnosis by means of bispectral index (BIS) with isoflurane. <i>IEEE Transactions on Biomedical Engineering</i> , 2001, 48, 874-889.	2.5	109



#	ARTICLE	IF	CITATIONS
400	Multitasked closed-loop control in anesthesia. IEEE Engineering in Medicine and Biology Magazine, 2001, 20, 39-53.	1.1	72
401	Monitoring the depth of anaesthesia using bispectral analysis and closed-loop controlled administration of propofol. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2001, 15, 83-96.	1.7	7
402	Induction and maintenance of intravenous anaesthesia using target-controlled infusion systems. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2001, 15, 19-33.	1.7	16
403	Target-controlled administration of inhaled anaesthetics. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2001, 15, 35-50.	1.7	1
404	Arteriovenous serum cocaine concentration difference after intravenous bolus injection and constant-rate infusions: relation to pharmacodynamic estimates in rats. European Journal of Pharmaceutical Sciences, 2001, 14, 261-269.	1.9	4
405	Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man. European Journal of Pharmaceutical Sciences, 2001, 14, 339-346.	1.9	8
406	A survey of fuzzy logic monitoring and control utilisation in medicine. Artificial Intelligence in Medicine, 2001, 21, 27-42.	3.8	114
407	A pharmacokinetic-dynamic explanation of the rapid onset-offset of rapacuronium. European Journal of Anaesthesiology, 2001, 18, 83-89.	0.7	3
408	Predictors of onset and offset of drug effect. European Journal of Anaesthesiology, 2001, 18, 26-31.	0.7	5
409	Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate. British Journal of Clinical Pharmacology, 2001, 52, 387-398.	1.1	15
410	Precurarization and Priming: A Theoretical Analysis of Safety and Timing. Anesthesia and Analgesia, 2001, 93, 1253-1256.	1.1	44
411	Pharmacokinetic-Pharmacodynamic Modeling of Rivastigmine, a Cholinesterase Inhibitor, in Patients with Alzheimer's Disease. Journal of Clinical Pharmacology, 2001, 41, 1082-1090.	1.0	40
412	Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Imipenem in Healthy Rats. Antimicrobial Agents and Chemotherapy, 2001, 45, 1682-1687.	1.4	15
413	Pharmacokinetic-Pharmacodynamic Modeling of Electroencephalogram Effect of Imipenem in Rats with Acute Renal Failure. Antimicrobial Agents and Chemotherapy, 2001, 45, 3607-3609.	1.4	5
414	Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABA <sub>A</sub> Receptor in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 616-626.	1.3	19
415	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Concentration-Dependent Hysteresis and Biphasic Electroencephalogram Effects of Alphaxalone in Rats. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 1158-1167.	1.3	51
416	Pharmacokinetic Model for Tobramycin in Acinetobacter Meningitis. Annals of Pharmacotherapy, 2002, 36, 83-86.	0.9	5
417	The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. Behavioural Pharmacology, 2002, 13, 93-103.	0.8	5



#	ARTICLE	IF	CITATIONS
418	Pharmacokinetic/Pharmacodynamic Modeling of Rocuronium in Myasthenic Patients Is Improved by Taking into Account the Number of Unbound Acetylcholine Receptors. <i>Anesthesia and Analgesia</i> , 2002, 95, 588-596.	1.1	7
419	Concentration-Effect Relation of Succinylcholine Chloride during Propofol Anesthesia. <i>Anesthesiology</i> , 2002, 97, 1082-1092.	1.3	31
420	Modeling of the Sedative and Airway Obstruction Effects of Propofol in Patients with Parkinson Disease undergoing Stereotactic Surgery. <i>Anesthesiology</i> , 2002, 97, 1378-1386.	1.3	39
421	Application of semilinear canonical correlation to the measurement of the electroencephalographic effects of volatile anaesthetics. <i>European Journal of Anaesthesiology</i> , 2002, 19, 735-741.	0.7	1
422	Pharmacokinetic/Pharmacodynamic Modeling of Rocuronium in Myasthenic Patients Is Improved by Taking into Account the Number of Unbound Acetylcholine Receptors. <i>Anesthesia and Analgesia</i> , 2002, 95, 588-596.	1.1	16
423	Population Pharmacodynamic Modeling without Plasma Concentrations of Rocuronium in Children. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 37-42.	1.0	4
424	Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. <i>AAPS PharmSci</i> , 2002, 4, 160-188.	1.3	83
425	Application of semilinear canonical correlation to the measurement of the electroencephalographic effects of volatile anaesthetics. <i>European Journal of Anaesthesiology</i> , 2002, 19, 735.	0.7	3
426	Pain model and fuzzy logic patient-controlled analgesia in shock-wave lithotripsy. <i>Medical and Biological Engineering and Computing</i> , 2002, 40, 128-136.	1.6	17
427	Influence of arterial vs. venous sampling site on nicotine tolerance model selection and parameter estimation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 49-66.	0.8	2
428	Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach. <i>Pharmaceutical Research</i> , 2002, 19, 858-867.	1.7	8
429	Physiologic-pharmacologic interpretation of the constants in the Hill equation for neuromuscular block: a hypothesis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 189-206.	0.8	3
430	Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. <i>AAPS PharmSci</i> , 2002, 4, 212-222.	1.3	115
431	Competition Between Acetylcholine and a Nondepolarizing Muscle Relaxant for Binding to the Postsynaptic Receptors at the Motor End Plate: Simulation of Twitch Strength and Neuromuscular Block. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2003, 30, 23-51.	0.8	9
432	A Pharmacokinetic-Pharmacodynamic Model for Neuromuscular Blocking Agents to Predict Train-of-Four Twitches. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2003, 30, 105-118.	0.8	2
433	Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT. <i>Journal of Neurology</i> , 2003, 250, 1475-1481.	1.8	10
434	Application of pharmacokinetic/pharmacodynamic and stochastic modelling to 6-mercaptopurine micronucleus induction in mouse bone marrow erythrocytes. <i>Journal of Applied Toxicology</i> , 2003, 23, 59-70.	1.4	4
435	Pharmacokinetic-Pharmacodynamic Modeling of Methotrexate-Induced Toxicity in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1654-1664.	1.6	33

#	ARTICLE	IF	CITATIONS
436	Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 348-365.	2.3	94
437	Drug metabolism and disposition in children. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 281-299.	1.0	160
438	Target concentration of propofol required to insert the laryngeal mask airway in children. <i>Paediatric Anaesthesia</i> , 2003, 13, 217-222.	0.6	14
439	Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 3-10.	1.1	9
440	Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Norfloxacin in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1952-1957.	1.4	7
441	Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 969-976.	1.3	45
442	Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. <i>British Journal of Anaesthesia</i> , 2003, 90, 183-188.	1.5	32
443	Pharmacological Agents That Directly Modulate Insulin Secretion. <i>Pharmacological Reviews</i> , 2003, 55, 105-131.	7.1	217
444	Diversity of Mechanism-Based Pharmacodynamic Models. <i>Drug Metabolism and Disposition</i> , 2003, 31, 510-518.	1.7	318
445	Pharmacokinetic/Pharmacodynamic Modeling of the Antinociceptive Effects of (+)-Tramadol in the Rat: Role of Cytochrome P450 2D Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 710-718.	1.3	47
446	Target-Controlled Infusion of Rocuronium in Infants, Children, and Adults: A Comparison of the Pharmacokinetic and Pharmacodynamic Relationship. <i>Anesthesia and Analgesia</i> , 2003, 97, 44-49.	1.1	30
447	The Influence of Hemorrhagic Shock on Etomidate: A Pharmacokinetic and Pharmacodynamic Analysis. <i>Anesthesia and Analgesia</i> , 2003, 96, 1360-1368.	1.1	47
448	The Pharmacokinetics and Pharmacodynamics of Propofol in a Modified Cyclodextrin Formulation (Captisol?) Versus Propofol in a Lipid Formulation (Diprivan?): An Electroencephalographic and Hemodynamic Study in a Porcine Model. <i>Anesthesia and Analgesia</i> , 2003, 97, 72-79.	1.1	70
449	The Role of Pharmacometrics in Cardiovascular Drug Development. , 2003, , 365-388.		1
450	An Approach to Predict the Ductus-Arteriosus Dilating Effect Induced by Lipo-Prostaglandin E1 in Newborn Rats Lacking Plasma Concentration-Time Data by the Pharmacological Response Kinetic Model.. <i>Biological and Pharmaceutical Bulletin</i> , 2003, 26, 210-215.	0.6	3
451	Pharmacodynamics and Pharmacogenomics of Corticosteroids: Microarray Studies. , 2004, , 85-103.		1
452	Model to describe the degree of twitch potentiation during neuromuscular monitoring. <i>British Journal of Anaesthesia</i> , 2004, 92, 373-380.	1.5	15
453	Pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of imipenem in rats with experimental hypovolaemia or endotoxaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 187-192.	1.3	4

#	ARTICLE	IF	CITATIONS
454	Comparison of BIS and AAI as measures of anaesthetic drug effect during desflurane-remifentanyl anaesthesia. <i>Acta Anaesthesiologica Scandinavica</i> , 2004, 48, 1168-1173.	0.7	20
455	Pharmacokinetic/pharmacodynamic models for the depletion of $V_{\beta 5.2/5.3}$ T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 378-389.	1.1	15
456	A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 618-631.	1.1	80
457	Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2004, 48, 1038-1048.	0.7	18
458	Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. <i>British Journal of Pharmacology</i> , 2004, 142, 323-330.	2.7	21
459	Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. <i>Brain Research</i> , 2004, 1023, 175-184.	1.1	44
460	Pharmacokinetics and Pharmacodynamics of Dexamethasone after Intravenous Administration in Camels: Effect of Dose. <i>Veterinary Research Communications</i> , 2004, 28, 525-542.	0.6	12
462	Grey-box pharmacokinetic/pharmacodynamic modelling of a euglycaemic clamp study. <i>Journal of Mathematical Biology</i> , 2004, 48, 591-604.	0.8	20
463	Use of population modeling to define rational monitoring of amiodarone hepatic effects*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 342-351.	2.3	30
464	Kinetics and EEG Effects of Midazolam during and after 1-Minute, 1-Hour, and 3-Hour Intravenous Infusions. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 605-611.	1.0	25
465	Recent advances in intravenous anaesthesia. <i>British Journal of Anaesthesia</i> , 2004, 93, 725-736.	1.5	78
466	Evaluation of Combination Chemotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7994-8004.	3.2	350
467	Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnotics. <i>Clinical Pharmacokinetics</i> , 2004, 43, 227-238.	1.6	211
468	The effect of cisatracurium and rocuronium on cisatracurium precurarization and the priming principle. <i>Journal of Clinical Anesthesia</i> , 2004, 16, 83-87.	0.7	11
470	An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. <i>European Journal of Anaesthesiology</i> , 2004, 21, 882-891.	0.7	2
471	A Comparison of Bispectral Index and Rapidly Extracted Auditory Evoked Potentials Index Responses to Noxious Stimulation During Sevoflurane Anesthesia. <i>Anesthesia and Analgesia</i> , 2004, 99, 1141-1146.	1.1	25
472	Comments on Using the Time of Maximum Effect Site Concentration to Combine Pharmacokinetics and Pharmacodynamics: In Reply. <i>Anesthesiology</i> , 2004, 100, 1320-1321.	1.3	1
473	Induction Speed Is Not a Determinant of Propofol Pharmacodynamics. <i>Anesthesiology</i> , 2004, 101, 1112-1121.	1.3	85

#	ARTICLE	IF	CITATIONS
474	Time to Maximum Effect Site Concentration. <i>Anesthesiology</i> , 2004, 100, 1319-1319.	1.3	0
475	Drugs and Human Memory (Part 2). <i>Anesthesiology</i> , 2004, 100, 1277-1297.	1.3	50
476	An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. <i>European Journal of Anaesthesiology</i> , 2004, 21, 882-891.	0.7	5
477	Spectral Entropy and Bispectral Index as Measures of the Electroencephalographic Effects of Sevoflurane. <i>Anesthesiology</i> , 2004, 101, 1275-1282.	1.3	124
478	Application of Bispectral Index® and Narcotrend® Index to the Measurement of the Electroencephalographic Effects of Isoflurane with and without Burst Suppression. <i>Anesthesiology</i> , 2004, 101, 847-854.	1.3	55
479	Pharmacokinetics-Pharmacodynamics During Drug Development – An Example from Servier: Ivabradine. <i>Therapie</i> , 2004, 59, 173-177.	0.6	0
481	Kinetics and Dynamics of Intravenous Adinazolam, N-Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 529-537.	1.0	28
482	Population pharmacokinetics/pharmacodynamics of anesthetics. <i>AAPS Journal</i> , 2005, 7, E383-E389.	2.2	12
483	Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments. <i>AAPS Journal</i> , 2005, 7, E759-E785.	2.2	32
484	Pharmacokinetic-Pharmacodynamic Modeling of Opioids. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 90-103.	0.6	165
485	Myasthenia gravis and myasthenic syndrome: Simulation of twitch strength with or without therapy. <i>Muscle and Nerve</i> , 2005, 32, 745-750.	1.0	1
486	Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 103-111.	0.8	12
488	Population Pharmacokinetic-Pharmacodynamic Modeling of Subcutaneous and Pulmonary Insulin in Rats. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 485-500.	0.8	17
489	Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 261-281.	0.8	31
490	Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 161-183.	0.8	87
491	How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 185-197.	0.8	127
492	Improving Pharmacokinetic-Pharmacodynamic Models of Muscle Relaxants Using Potentiation Modelling. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2005, 32, 143-154.	0.8	5
493	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling – A New Classification of Biomarkers. <i>Pharmaceutical Research</i> , 2005, 22, 1432-1437.	1.7	160

#	ARTICLE	IF	CITATIONS
494	Volume of the effect compartment in simulations of neuromuscular block. <i>Theoretical Biology and Medical Modelling</i> , 2005, 2, 41.	2.1	3
495	A semi-parametric approach to fitting a nonlinear mixed PK/PD model with an effect compartment using SAS. <i>Pharmaceutical Statistics</i> , 2005, 4, 59-69.	0.7	2
496	<i>Pharmakodynamik.</i> , 2005, , 18-23.		0
497	Interstitial muscle concentrations of rocuronium under steady-state conditions in anaesthetized dogs: actual versus predicted values. <i>British Journal of Anaesthesia</i> , 2005, 94, 49-56.	1.5	14
498	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 816-825.	1.3	38
499	Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1136-1149.	1.3	103
500	Impact of peripheral elimination on the concentrationâ€“effect relationship of remifentanyl in anaesthetized dogs â€“. <i>British Journal of Anaesthesia</i> , 2005, 94, 357-365.	1.5	14
501	Introduction to Automated Drug Delivery in Clinical Anesthesia. <i>European Journal of Control</i> , 2005, 11, 535-557.	1.6	73
502	Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 447-471.	1.5	109
503	Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. <i>Clinical Pharmacokinetics</i> , 2005, 44, 331-347.	1.6	128
504	Modelling the Anti-Migraine Effects of BIBN 4096 BS. <i>Clinical Pharmacokinetics</i> , 2006, 45, 715-728.	1.6	15
505	Fatal Respiratory Depression after??Multiple Intravenous Morphine Injections. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1051-1060.	1.6	75
506	Spectral Entropy and Bispectral Index as Measures of the Electroencephalographic Effects of Propofol. <i>Anesthesia and Analgesia</i> , 2006, 102, 1456-1462.	1.1	44
508	A-Line, Bispectral Index, and Estimated Effect-Site Concentrations: A Prediction of Clinical End-Points of Anesthesia. <i>Anesthesia and Analgesia</i> , 2006, 102, 1141-1146.	1.1	16
509	Impact of Hypothermia on the Response to Neuromuscular Blocking Drugs. <i>Anesthesiology</i> , 2006, 104, 1070-1080.	1.3	120
510	Pharmacologic Management of Dental Anxiety. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 1-3.	0.7	7
511	Population Pharmacokinetic and Pharmacodynamic Analysis of a Class IC Antiarrhythmic, Pilsicainide, in Patients With Cardiac Arrhythmias. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 59-68.	1.0	6
512	An effective correlation dimension and burst suppression ratio of the EEG in rat. Correlation with sevoflurane induced anaesthetic depth. <i>European Journal of Anaesthesiology</i> , 2006, 23, 391-402.	0.7	23

#	ARTICLE	IF	CITATIONS
513	Population Pharmacokinetics of Metformin in Late Pregnancy. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 67-72.	1.0	165
514	Suppression of the human spinal H-reflex by propofol: a quantitative analysis. <i>Acta Anaesthesiologica Scandinavica</i> , 2006, 50, 193-200.	0.7	23
515	Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. <i>Paediatric Anaesthesia</i> , 2006, 16, 761-768.	0.6	16
516	Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 177-190.	1.1	77
517	Relevance of frequent $\mu$ -opioid receptor polymorphisms for opioid activity in healthy volunteers. <i>Pharmacogenomics Journal</i> , 2006, 6, 200-210.	0.9	80
518	Evidence for morphine-independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 35-48.	2.3	68
519	Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 72-89.	2.3	91
520	Population Pharmacokinetic/Pharmacodynamic Modelling of the Analgesic Effects of Tramadol in Pediatrics. <i>Pharmaceutical Research</i> , 2006, 23, 2014-2023.	1.7	554
521	Pharmacokinetic-Pharmacodynamic Modelling: History and Perspectives. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 227-279.	0.8	147
522	Twitch Potentiation Influences the Time Course of Twitch Depression in Muscle Relaxant Studies: A Pharmacokinetic-Pharmacodynamic Explanation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2006, 33, 795-806.	0.8	0
523	Population clinical pharmacology of children: modelling covariate effects. <i>European Journal of Pediatrics</i> , 2006, 165, 819-829.	1.3	158
524	Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: A potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 91-101.	1.9	18
525	Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: Application to escitalopram-induced effects on brain serotonin levels. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 29, 394-404.	1.9	39
526	Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs. <i>Journal of Pharmacological and Toxicological Methods</i> , 2006, 53, 174-183.	0.3	44
527	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 682-692.	1.3	39
528	Modeling Drug- and System-Related Changes in Body Temperature: Application to Clomethiazole-Induced Hypothermia, Long-Lasting Tolerance Development, and Circadian Rhythm in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 209-219.	1.3	8
529	Application of microdialysis for pharmacokinetic-pharmacodynamic modelling. <i>Expert Opinion on Drug Discovery</i> , 2006, 1, 289-301.	2.5	10
530	Dose Response: Pharmacokinetic-Pharmacodynamic Approach. , 2006, , 73-88.		5



#	ARTICLE	IF	CITATIONS
531	Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 598-607.	1.3	36
532	Estimation of the plasma effect-site equilibration rate constant ( $k_{e0}$ ) of rocuronium by the time of maximum effect: a comparison with non-parametric and parametric approaches. <i>British Journal of Anaesthesia</i> , 2007, 99, 679-685.	1.5	8
533	Applicability of the Dopamine and Rate Hypotheses in Explaining the Differences in Behavioral Pharmacology of the Chloro-Benzotropine Analogs: Studies Conducted Using Intracerebral Microdialysis and Population Pharmacodynamic Modeling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 760-769.	1.3	4
534	Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 128-136.	1.4	143
535	Pharmacokinetics/Pharmacodynamics of Acetaminophen Analgesia in Japanese Patients with Chronic Pain. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 157-161.	0.6	39
536	Propofol and Remifentanyl Effect-site Concentrations Estimated by Pharmacokinetic Simulation and Bispectral Index Monitoring During Craniotomy With Intraoperative Awakening for Brain Tumor Resection. <i>Journal of Neurosurgical Anesthesiology</i> , 2007, 19, 183-189.	0.6	46
537	Caffeine Accelerates Absorption and Enhances the Analgesic Effect of Acetaminophen. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 715-726.	1.0	75
538	An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose Provocations. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1159-1171.	1.0	89
539	Automatic drug delivery in anesthesia: From the beginning until now. , 2007, , .		9
540	Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine. <i>Clinical Pharmacokinetics</i> , 2007, 46, 433-447.	1.6	34
541	Integrated Pharmacokinetics and Pharmacodynamics in Drug Development. <i>Clinical Pharmacokinetics</i> , 2007, 46, 713-737.	1.6	57
542	Time Course of Drug Response. , 2007, , 301-311.		1
543	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration-Effect Relationships Application in Drug Candidate Selection and Lead Optimization. , 2007, , 885-908.		5
544	Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an Iterative Two-Stage Bayesian technique. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 455-473.	1.1	13
545	The Partial 5-Hydroxytryptamine <sub>1A</sub> Receptor Agonist Buspirone does not Antagonize Morphine-induced Respiratory Depression in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 59-68.	2.3	50
546	Mechanism-based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 50-58.	2.3	89
547	Modeling of Brain D <sub>2</sub> Receptor Occupancy-Plasma Concentration Relationships with a Novel Antipsychotic, YKP1358, Using Serial PET Scans in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 252-258.	2.3	31
548	Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 3-6.	2.3	29

#	ARTICLE	IF	CITATIONS
549	Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. <i>British Journal of Pharmacology</i> , 2007, 151, 713-720.	2.7	23
550	Sevoflurane increases fade of neuromuscular response to TOF stimulation following rocuronium administration in children. A PK/PD analysis. <i>Paediatric Anaesthesia</i> , 2007, 17, 637-646.	0.6	11
551	Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution, Receptor Theory, and Dynamical Systems Analysis. <i>Annual Review of Pharmacology and Toxicology</i> , 2007, 47, 357-400.	4.2	228
552	Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1045-1054.	0.8	6
553	Reply to Dr. MÃgarbane et al. regarding "Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose". <i>Intensive Care Medicine</i> , 2007, 33, 197-197.	3.9	5
554	Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the Kâ€PD Model. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2007, 34, 57-85.	0.8	141
555	Pharmacokinetic-Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats. <i>Pharmaceutical Research</i> , 2008, 25, 183-193.	1.7	62
556	Semi-mechanistic Pharmacokinetic/Pharmacodynamic Modelling of the Antinociceptive Response in the Presence of Competitive Antagonism: The Interaction Between Tramadol and its Active Metabolite on $\mu$ -Opioid Agonism and Monoamine Reuptake Inhibition, in the Rat. <i>Pharmaceutical Research</i> , 2008, 25, 1789-1797.	1.7	12
557	PK/PD Modelling and Beyond: Impact on Drug Development. <i>Pharmaceutical Research</i> , 2008, 25, 2720-2722.	1.7	21
558	Failure of Two Commercial Indexes and Spectral Parameters to Reflect the Pharmacodynamic Effect of Desflurane on EEG. <i>Journal of Clinical Monitoring and Computing</i> , 2008, 22, 149-158.	0.7	19
559	Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 139-157.	0.8	54
560	An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2008, 35, 619-633.	0.8	24
561	Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 795-806.	0.8	20
562	Progress of automatic drug delivery in anaesthesiaâ€The â€Rostock assistant system for anaesthesia control (RAN)â€™. <i>International Journal of Adaptive Control and Signal Processing</i> , 2009, 23, 504-521.	2.3	10
563	Simulated Drug Administration: An Emerging Tool for Teaching Clinical Pharmacology During Anesthesiology Training. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 170-174.	2.3	38
564	Pharmacokinetics and Pharmacodynamics of Intravenously Administered Anesthetic Drugs: Concepts and Lessons for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 153-157.	2.3	21
565	Anesthesia: A Discipline That Incorporates Clinical Pharmacology Across the DDRU Continuum. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 3-6.	2.3	7
566	Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5â€hydroxytryptamine reuptake inhibitors in mice. <i>British Journal of Pharmacology</i> , 2008, 155, 276-284.	2.7	40



#	ARTICLE	IF	CITATIONS
567	Contributions of PK/PD Modeling to Intravenous Anesthesia. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 27-38.	2.3	67
568	PHARMACOKINETICS AND PHARMACODYNAMICS OF INDOMETHACIN: EFFECTS ON CEREBRAL BLOOD FLOW IN ANAESTHETIZED SHEEP. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 317-323.	0.9	12
569	Using pharmacokineticâ€”pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. <i>European Journal of Pharmacology</i> , 2008, 584, 318-327.	1.7	63
570	Mathematical properties and parameter estimation for transit compartment pharmacodynamic models. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 34, 104-109.	1.9	6
571	Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: The role of complex biophase distribution kinetics. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 34, 149-163.	1.9	28
572	Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2008, 47, 417-448.	1.6	83
573	Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2008, 47, 721-731.	1.6	15
574	Analysis of depth of anesthesia with Hilbertâ€”Huang spectral entropy. <i>Clinical Neurophysiology</i> , 2008, 119, 2465-2475.	0.7	102
575	Anesthesia for Patients Undergoing Renal Transplantation. , 2008, , 187-209.		0
576	Paracetamol (acetaminophen) pharmacodynamics: interpreting the plasma concentration. <i>Archives of Disease in Childhood</i> , 2008, 93, 241-247.	1.0	92
578	Drug evaluation of clevidipine for acute hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2519-2529.	0.9	12
579	In Vitro and In Vivo Pharmacodynamic Properties of Metoprolol in Fructose-fed Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 532-541.	0.8	16
580	On the modeling of drug induced respiratory depression in the non-steady-state. , 2008, 2008, 5564-8.		4
581	Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1267-1274.	1.7	92
582	Pharmacokinetic/pharmacodynamic modeling of cardiac toxicity in human acute overdoses: utility and limitations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 569-579.	1.5	8
583	Pharmacokinetics and Pharmacodynamics That Make Sense. <i>Refresher Courses in Anesthesiology</i> , 2008, 36, 45-59.	0.1	1
584	The Influence of Age on the Dynamic Relationship Between End-Tidal Sevoflurane Concentrations and Bispectral Index. <i>Anesthesia and Analgesia</i> , 2008, 107, 1566-1572.	1.1	33
586	Using Permutation Entropy to Measure the Electroencephalographic Effects of Sevoflurane. <i>Anesthesiology</i> , 2008, 109, 448-456.	1.3	180

#	ARTICLE	IF	CITATIONS
587	Automatic drug delivery in anesthesia - the design of an anesthesia assistant system. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2008, 41, 9601-9606.	0.4	3
588	Is time to peak effect of neuromuscular blocking agents dependent on dose? Testing the concept of buffered diffusion. European Journal of Anaesthesiology, 2008, 25, 572-580.	0.7	4
589	Comparison between Bispectral Index and Patient State Index as Measures of the Electroencephalographic Effects of Sevoflurane. Anesthesiology, 2008, 109, 799-805.	1.3	63
590	Comparative Pharmacodynamic Modeling Using Bispectral and Narcotrend-Index With and Without a Pharmacodynamic Plateau During Sevoflurane Anesthesia. Anesthesia and Analgesia, 2008, 106, 1171-1181.	1.1	20
591	The Dynamic Relationship Between End-Tidal Sevoflurane Concentrations, Bispectral Index, and Cerebral State Index in Children. Anesthesia and Analgesia, 2008, 107, 1573-1578.	1.1	17
592	Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling. Drug Metabolism and Pharmacokinetics, 2009, 24, 3-15.	1.1	69
593	Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against <i>Pseudomonas aeruginosa</i> . Antimicrobial Agents and Chemotherapy, 2009, 53, 46-56.	1.4	88
594	Comparative Pharmacodynamics of Olmesartan and Azelnidipine in Patients with Hypertension: a Population Pharmacokinetic/Pharmacodynamic Analysis. Drug Metabolism and Pharmacokinetics, 2009, 24, 376-388.	1.1	20
595	SIMULTANEOUS MODELING OF PHARMACOKINETICS AND PHARMACODYNAMICS FOR ERGOTAMINE IN MIGRAINE PATIENTS.. Acta Neurologica Scandinavica, 2009, 65, 85-86.	1.0	0
596	Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discovery Today, 2009, 14, 358-372.	3.2	101
597	Semi-mechanistic pharmacodynamic modelling of gene expression and silencing processes. European Journal of Pharmaceutical Sciences, 2009, 37, 418-426.	1.9	14
598	Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on <i>in vivo</i> D <sub>2</sub> receptor occupancy and behavioural conditioned avoidance response. Biopharmaceutics and Drug Disposition, 2009, 30, 209-220.	1.1	10
599	Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients. Pharmaceutical Research, 2009, 26, 1952-1962.	1.7	14
600	The time course of drug effects. Pharmaceutical Statistics, 2009, 8, 176-185.	0.7	15
601	Pharmacokinetic-pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against <i>Helicobacter pylori</i> . British Journal of Clinical Pharmacology, 2009, 67, 503-510.	1.1	14
602	Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework*. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 2-12.	1.2	21
603	Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs. British Journal of Pharmacology, 2009, 158, 1982-1995.	2.7	21
604	Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Medicinal Chemistry, 2009, 1, 1371-1374.	1.1	35

#	ARTICLE	IF	CITATIONS
607	From pharmacokinetics to therapeutics. <i>Drug Metabolism Reviews</i> , 2009, 41, 455-474.	1.5	3
608	Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR $\alpha$ , a Novel Liver X Receptor Agonist, in Healthy Participants. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 643-649.	1.0	168
609	Estimating Depth of Anesthesia with Sparsity Measure of EEG Data in Wavelet Domain. , 2009, , .		0
610	Competitive Substrates for P-Glycoprotein and Organic Anion Protein Transporters Differentially Reduce Blood Organ Transport of Fentanyl and Loperamide: Pharmacokinetics and Pharmacodynamics in Sprague-Dawley Rats. <i>Anesthesia and Analgesia</i> , 2009, 108, 149-159.	1.1	38
611	Maximizing Prediction Probability P K as an Alternative Semiparametric Approach to Estimate the Plasma Effect-Site Equilibration Rate Constant $k_{e0}$ . <i>Anesthesia and Analgesia</i> , 2009, 109, 1470-1478.	1.1	8
612	Population pharmacokinetics and pharmacodynamics in anesthesia, intensive care and pain medicine. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 479-484.	0.9	21
614	Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems. <i>AAPS Journal</i> , 2010, 12, 1-10.	2.2	53
615	Prediction of Exposure-Response Relationships to Support First-in-Human Study Design. <i>AAPS Journal</i> , 2010, 12, 750-758.	2.2	36
616	Pharmacodynamics of S-2150, a Simultaneous Calcium-blocking and $\beta$ -1-Inhibiting Antihypertensive Drug, in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 273-280.	1.2	0
617	Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 1075-1083.	1.2	25
618	Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1235-1246.	1.2	15
619	Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 791-800.	1.2	20
620	A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 347-363.	0.8	55
621	Population Pharmacokinetic Analysis of Blood and Joint Synovial Fluid Concentrations of Robenacoxib from Healthy Dogs and Dogs with Osteoarthritis. <i>Pharmaceutical Research</i> , 2010, 27, 2633-2645.	1.7	26
622	The pharmacology of anaesthetics in the neonate. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2010, 24, 419-431.	1.7	29
624	Pharmacodynamic Differentiation of Lorazepam Sleepiness and Dizziness Using an Ordered Categorical Measure. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 3628-3641.	1.6	4
625	Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats. <i>British Journal of Pharmacology</i> , 2010, 159, 176-187.	2.7	9
626	Long-lasting target binding and rebinding as mechanisms to prolong <i>in vivo</i> drug action. <i>British Journal of Pharmacology</i> , 2010, 161, 488-508.	2.7	250

#	ARTICLE	IF	CITATIONS
627	Pediatric models for adult target-controlled infusion pumps. <i>Paediatric Anaesthesia</i> , 2010, 20, 223-232.	0.6	62
628	Leaving no stone unturned, or extracting blood from stone?. <i>Paediatric Anaesthesia</i> , 2010, 20, 1-6.	0.6	10
630	Quantifying Pain Relief Following Administration of a Novel Formulation of Paracetamol (Acetaminophen). <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1406-1413.	1.0	5
631	Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 418-429.	1.1	18
632	Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. <i>British Journal of Anaesthesia</i> , 2010, 105, 172-178.	1.5	52
634	Lu AE58054, a 5-HT <sub>6</sub> antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1021-1033.	1.0	100
635	Electrocardiographic assessment for therapeutic proteins—scientific discussion. <i>American Heart Journal</i> , 2010, 160, 627-634.	1.2	35
636	Pharmacokinetics I: PK-PD approaches - antibiotic drug development. , 2010, , 143-155.		0
637	Pharmacometrics 2020. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 151S-157S.	1.0	41
638	Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 719-728.	1.3	37
639	Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 (11 $\beta$ -HSD1) Activity After Oral Administration of AMG 221, a Selective 11 $\beta$ -HSD1 Inhibitor. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 830-841.	1.0	36
640	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4619-4630.	1.4	198
641	Pharmacokinetic-pharmacodynamic Modeling of Monoamine Oxidase A Inhibitory Activity and Behavior Improvement by Curcumin in the Mouse Forced Swimming Test. <i>Chinese Journal of Natural Medicines</i> , 2011, 9, 293-304.	0.7	4
643	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Fimasartan Following Single and Repeated Oral Administration in the Fasted and Fed States in Healthy Subjects. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 335-346.	1.0	39
644	Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 739-750.	1.6	65
646	Clinical Evaluation of Two Ke <sub>0</sub> in the same Pharmacokinetic Propofol Model: Study on Loss and Recovery of Consciousness. <i>Revista Brasileira De Anestesiologia</i> , 2011, 61, 397-408.	0.6	7
647	Toxicodynamic Analysis of Cardiac Effects Induced by Four Cholinesterase Inhibitors in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 48, 935-939.	1.2	5
648	Relationship between Plasma Concentration and Antihypertensive Effect of the Dihydropyridine Calcium Antagonist, Benidipine, in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 1200-1204.	1.2	8

#	ARTICLE	IF	CITATIONS
649	Pharmacokinetics and Kinetic-Dynamic Modelling of Aminophenones as Methaemoglobin Formers. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 282-287.	1.2	7
650	A Comparative Pharmacokinetic-Pharmacodynamic Study of the Electrocardiographic Effects of Epinastine and Terfenadine in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 458-462.	1.2	21
651	A Pharmacokinetic-Pharmacodynamic Model for Duodenal Levodopa Infusion. <i>Clinical Neuropharmacology</i> , 2011, 34, 61-65.	0.2	30
652	Principles of pharmacokinetics. , 0, , 57-71.		0
653	Drugs for reversal of neuromuscular blockade. , 0, , 633-647.		0
654	An Evaluation of Using Population Pharmacokinetic Models to Estimate Pharmacodynamic Parameters for Propofol and Bispectral Index in Children. <i>Anesthesiology</i> , 2011, 115, 83-93.	1.3	72
655	Pharmacokinetic and Pharmacodynamic Studies of the Histamine H1-Receptor Antagonist Ebastine in Dogs. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 46, 596-599.	1.2	8
656	Pharmacokinetics and brain entry of alaptide, a novel nootropic agent, in mice, rats and rabbits. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 43, 874-876.	1.2	8
657	Obesity Does Not Influence the Onset and Offset of Sevoflurane Effect as Measured by the Hysteresis Between Sevoflurane Concentration and Bispectral Index. <i>Anesthesia and Analgesia</i> , 2011, 113, 70-76.	1.1	11
658	A Pharmacodynamic Model to Predict the Time Dependent Adaptation of Dopaminergic Activity During Constant Concentrations of Haloperidol*. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 42, 566-571.	1.2	4
659	A Pharmacokinetic-pharmacodynamic Linking Model for the $\alpha_2$ -Adrenergic Antagonism of Idazoxan on Clonidine-induced Mydriasis in the Rat. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 47, 157-161.	1.2	4
660	Alcuronium pharmacodynamics in dogs: effect-concentration relationships in the diaphragmatic and limb muscles. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 39, 614-620.	1.2	1
661	Brain as an eliminating organ?. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 946-946.	1.2	1
662	Chronopharmacological Assessment Identified GLUT4 as a Factor Responsible for the Circadian Variation of the Hypoglycemic Effect of Tolbutamide in Rats. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 503-515.	1.1	5
663	Buprenorphine TTS for children â€” a review of the drugâ€™s clinical pharmacology. <i>Paediatric Anaesthesia</i> , 2011, 21, 280-290.	0.6	26
664	Understanding the time course of pharmacological effect: a PKPD approach. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 815-823.	1.1	74
665	Population pharmacokineticâ€”pharmacodynamic analysis for sugammadexâ€”mediated reversal of rocuroniumâ€”induced neuromuscular blockade. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 415-433.	1.1	42
666	Pharmacokinetic/Pharmacodynamic Relationships of Transdermal Buprenorphine and Fentanyl in Experimental Human Pain Models. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 274-284.	1.2	36

#	ARTICLE	IF	CITATIONS
667	A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011, 63, 123-133.	0.3	9
668	Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects. <i>AAPS Journal</i> , 2011, 13, 650-661.	2.2	11
669	Holford NHG and Sheiner LB "Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models"; <i>Clin Pharmacokin</i> 6:429-453 (1981)"The Backstory. <i>AAPS Journal</i> , 2011, 13, 662-664.	2.2	23
670	A new stochastic approach to multi-compartment pharmacokinetic models: probability of traveling route and distribution of residence time in linear and nonlinear systems. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 83-104.	0.8	9
671	Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models. <i>Pharmaceutical Research</i> , 2011, 28, 2610-2627.	1.7	12
672	Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1517-1527.	1.1	11
673	Preclinical Prediction of Human Brain Target Site Concentrations: Considerations in Extrapolating to the Clinical Setting. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3577-3593.	1.6	67
674	Comparison between cerebral state index and bispectral index as measures of electroencephalographic effects of sevoflurane using combined sigmoidal Emax model. <i>Acta Pharmacologica Sinica</i> , 2011, 32, 1208-1214.	2.8	5
675	Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1152-1162.	1.0	150
676	Optimizing intravenous drug administration by applying pharmacokinetic/pharmacodynamic concepts. <i>British Journal of Anaesthesia</i> , 2011, 107, 38-47.	1.5	55
677	Predicting <i>In Vitro</i> Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1571-1579.	1.4	40
678	Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available Heat Shock Protein 90 Inhibitor in a Human Tumor Xenograft Mouse Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 964-973.	1.3	29
679	The peak bispectral index time cannot predict early phase propofol pharmacodynamics with effect site-controlled infusion algorithm. <i>Indian Journal of Pharmacology</i> , 2012, 44, 41.	0.4	2
680	Romiplostim Dose Response in Patients With Immune Thrombocytopenia. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1540-1551.	1.0	12
681	Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin-Like Growth Factor 1. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 487-498.	1.0	9
682	Pharmacokinetic-Pharmacodynamic Model of Newly Developed Dexibuprofen Sustained Release Formulations. <i>ISRN Pharmaceutics</i> , 2012, 2012, 1-7.	1.0	0
684	EPSAC Predictive Control Applied to Muscle Relaxant Administration. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2012, 45, 331-336.	0.4	2
685	Pharmacokinetics in Clinical Oncology. , 2012, , 53-72.		1



#	ARTICLE	IF	CITATIONS
686	Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 759-768.	2.4	28
687	Time Course of Drug Response. , 2012, , 357-367.		0
688	Pharmacodynamic Models for Discrete Data. <i>Clinical Pharmacokinetics</i> , 2012, 51, 767-786.	1.6	6
689	Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep. <i>British Journal of Pharmacology</i> , 2012, 166, 1916-1925.	2.7	16
690	Impact of the Pharmaceutical Sciences on Health Care: A Reflection over the Past 50 Years. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4075-4099.	1.6	32
691	Application of pharmacokineticsâ€“pharmacodynamics/clinical response modeling and simulation for biologics drug development. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 4367-4382.	1.6	29
692	Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 1013-1022.	1.1	20
694	Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1473-1481.	0.8	2
695	Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. <i>Acta Pharmacologica Sinica</i> , 2012, 33, 1379-1386.	2.8	19
697	Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 239-250.	1.1	19
698	Biomarkers and Therapeutic Drug Monitoring in Psychiatry. , 0, , .		3
699	Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 549-557.	1.3	62
700	Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers. <i>Pharmaceutical Research</i> , 2012, 29, 1518-1529.	1.7	13
701	Influence of real-time Bayesian forecasting of pharmacokinetic parameters on the precision of a rocuronium target-controlled infusion. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1025-1031.	0.8	12
702	Effect of anti-DR5 and chemotherapy on basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 417-426.	1.1	33
703	The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 741-749.	1.1	12
704	A Monitor-Decoupled Pharmacodynamic Model of Propofol in Children Using State Entropy as Clinical Endpoint. <i>IEEE Transactions on Biomedical Engineering</i> , 2012, 59, 736-743.	2.5	6
705	Ocular Pharmacokinetics of a Novel Tetrahydroquinoline Analog in Rabbit: Compartmental Analysis and PKâ€“PD Evaluation. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 414-423.	1.6	14

#	ARTICLE	IF	CITATIONS
706	In Vivo and Ex Vivo Inhibition of Spinal Nerve Ligation-Induced Ectopic Activity by Sodium Channel Blockers Correlate to In Vitro Inhibition of NaV1.7 and Clinical Efficacy: A Pharmacokinetic-Pharmacodynamic Translational Approach. <i>Pharmaceutical Research</i> , 2013, 30, 1409-1422.	1.7	5
707	Joint Population Pharmacokinetic/Pharmacodynamic Model for the Heart Rate Effects at Rest and at the End of Exercise for Cilobradine. <i>Pharmaceutical Research</i> , 2013, 30, 1110-1122.	1.7	5
708	Dose finding by concentration-response versus dose-response: a simulation-based comparison. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1391-1399.	0.8	6
709	Halogenated volatile anesthetics alter brain metabolism as revealed by proton magnetic resonance spectroscopy of mice in vivo. <i>NeuroImage</i> , 2013, 69, 244-255.	2.1	63
710	Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib. <i>AAPS Journal</i> , 2013, 15, 354-366.	2.2	46
711	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. <i>Pharmacological Reviews</i> , 2013, 65, 1053-1090.	7.1	248
712	Moving from Basic Toward Systems Pharmacodynamic Models. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2930-2940.	1.6	70
713	Multivariable Type-2 Self-Organizing Fuzzy Logic Controllers for Regulating Anesthesia with Rule Base Extraction. , 2013, , .		2
714	Pharmacokinetics of Non-Intravenous Formulations of Fentanyl. <i>Clinical Pharmacokinetics</i> , 2013, 52, 23-36.	1.6	107
715	Effect-site estimation of volatile anaesthetic agents: Beyond MAC fractions as a target for anaesthesia delivery. <i>Trends in Anaesthesia and Critical Care</i> , 2013, 3, 211-215.	0.4	2
716	Individualized closed-loop control of propofol anesthesia: A preliminary study. <i>Biomedical Signal Processing and Control</i> , 2013, 8, 500-508.	3.5	78
718	Population Pharmacokinetics. , 2013, , 1211-1218.		0
720	An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 64-72.	2.5	46
721	Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. <i>Psychopharmacology</i> , 2013, 229, 295-306.	1.5	107
722	Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human. <i>Journal of Pharmacological and Toxicological Methods</i> , 2013, 68, 357-366.	0.3	37
723	A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 589-600.	1.0	19
724	Management Principles to Reduce the Risk of Residual Neuromuscular Blockade. <i>Current Anesthesiology Reports</i> , 2013, 3, 130-138.	0.9	6
725	PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	1.3	43



#	ARTICLE	IF	CITATIONS
726	Bispectral Index Dynamics During Propofol Hypnosis Is Similar in Red-Haired and Dark-Haired Subjects. <i>Anesthesia and Analgesia</i> , 2013, 116, 319-326.	1.1	4
727	Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: A review. <i>Cephalalgia</i> , 2013, 33, 1122-1131.	1.8	15
728	Simulation of the Kinetics of Neuromuscular Block. <i>Anesthesia and Analgesia</i> , 2013, 117, 792-802.	1.1	3
729	Predicted heart rate effect of inhaled $\beta_2$ -adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 752-762.	1.1	6
730	Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics. , 2013, , 20-42.		3
732	Assessing the Utility of the Utility Function. <i>Anesthesiology</i> , 2013, 119, 504-506.	1.3	14
735	Modeling the Influence of the A118G Polymorphism in the OPRM1 Gene and of Noxious Stimulation on the Synergistic Relation between Propofol and Remifentanyl. <i>Anesthesiology</i> , 2013, 118, 1395-1407.	1.3	20
736	Performance Analysis of Extracted Rule-Base Multivariable Type-2 Self-Organizing Fuzzy Logic Controller Applied to Anesthesia. <i>BioMed Research International</i> , 2014, 2014, 1-19.	0.9	10
738	Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-16.	1.3	189
739	Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs. <i>Xenobiotica</i> , 2014, 44, 975-987.	0.5	6
740	A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 276-283.	0.8	23
741	Time-varying spectral analysis revealing differential effects of sevoflurane anaesthesia: non-rhythmic-to-rhythmic ratio. <i>Acta Anaesthesiologica Scandinavica</i> , 2014, 58, 157-167.	0.7	24
742	PKPD Aspects of Brain Drug Delivery in a Translational Perspective. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 233-268.	0.2	1
743	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 1-64.	0.2	8
744	Performance of Propofol Target-Controlled Infusion Models in the Obese. <i>Anesthesia and Analgesia</i> , 2014, 119, 302-310.	1.1	72
745	Cisatracurium dose-response relationship in patients with chronic liver disease. <i>Egyptian Journal of Anaesthesia</i> , 2014, 30, 197-202.	0.2	4
746	Time of effect duration and administration interval for sitagliptin in patients with kidney failure. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2014, 39, 77-85.	0.6	6
747	Pharmacokinetic-pharmacodynamic evaluation of the major component astragaloside IV on the immunomodulatory effects of Yu-ping-feng prescription. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2014, 39, 103-110.	0.6	15

#	ARTICLE	IF	CITATIONS
748	Subcellular drug targeting, pharmacokinetics and bioavailability. <i>Journal of Drug Targeting</i> , 2014, 22, 95-115.	2.1	15
751	Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014, 41, 291-318.	0.8	30
752	Safety prediction of topically exposed biocides using permeability coefficients and the desquamation rate at the stratum corneum. <i>Journal of Toxicological Sciences</i> , 2014, 39, 475-485.	0.7	8
755	Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 12-27.	1.3	66
756	Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 622-629.	2.3	47
757	Mixed-effects modeling of clinical DCE-MRI data: Application to colorectal liver metastases treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 132-141.	1.9	9
758	Comparison of propofol pharmacokinetic and pharmacodynamic models for awake craniotomy. <i>European Journal of Anaesthesiology</i> , 2015, 32, 527-534.	0.7	11
759	Pharmacokinetic-pharmacodynamic relationship of anesthetic drugs: from modeling to clinical use. <i>PLoS ONE</i> , 2015, 10, e0128912.	0.8	7
760	Discovery and Current Status of Evaluation System of Bioavailability and Related Pharmaceutical Technologies for Traditional Chinese Medicines—Flos Lonicerae Japonicae—Fructus Forsythiae Herb Couples as an Example. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28812-28840.	1.8	10
761	Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies. <i>PLoS ONE</i> , 2015, 10, e0117355.	1.1	7
762	PK/PD of Opioids. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2015, 41, 497-505.	0.0	0
764	Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children. <i>AAPS Journal</i> , 2015, 17, 1157-1167.	2.2	5
765	Methadone Recycling Sustains Drug Reservoir in Tissue. <i>Journal of Pain and Palliative Care Pharmacotherapy</i> , 2015, 29, 261-271.	0.5	1
766	A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 106-115.	1.3	3
767	Time Delays in Drug Administration: Effect, Transit, Tricks and Oscillations—Financial support of the Natural Sciences and Engineering Research Council (NSERC, Canada) [Discovery Grant to JB], the Fonds de Recherche en Santé Québec (FRQS, Québec) [Team Grant to JB and Doctoral Fellowship to AR] and Université de Montréal is acknowledged. <i>IFAC-PapersOnLine</i> , 2015, 48, 111-116.	0.5	1
768	Automation of anaesthesia: a review on multivariable control. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 231-239.	0.7	19
769	Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1393-1408.	1.5	14
770	Pharmacokinetic-pharmacodynamic modelling in anaesthesia. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 72-84.	1.1	29

#	ARTICLE	IF	CITATIONS
771	Effects of Idazoxan on Alcohol Pharmacokinetics and Intoxication: A Preliminary Human Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 594-602.	1.4	12
772	Perspectives on the history and scientific contributions of Gerhard Levy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 429-446.	0.8	6
773	Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2015, 42, 447-462.	0.8	20
774	Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase. <i>Drug Metabolism and Disposition</i> , 2015, 43, 54-62.	1.7	21
775	A Mathematical Model of Levodopa Medication Effect on Basal Ganglia in Parkinson's Disease: An Application to the Alternate Finger Tapping Task. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 280.	1.0	20
776	Parameter Identifiability of Fundamental Pharmacodynamic Models. <i>Frontiers in Physiology</i> , 2016, 7, 590.	1.3	34
777	The History of Target-Controlled Infusion. <i>Anesthesia and Analgesia</i> , 2016, 122, 56-69.	1.1	105
778	Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. <i>Acta Anaesthesiologica Scandinavica</i> , 2016, 60, 734-746.	0.7	8
779	Effects of target binding kinetics on <i>in vivo</i> drug efficacy: $k_{off}$ , $k_{on}$ and rebinding. <i>British Journal of Pharmacology</i> , 2016, 173, 2319-2334.	2.7	94
780	Systems Pharmacology and Pharmacodynamics: An Introduction. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 3-14.	0.2	4
781	Systems Pharmacology: An Overview. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 53-80.	0.2	7
782	Direct, Indirect, and Signal Transduction Response Modeling. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 177-209.	0.2	1
784	Classical Pharmacodynamics. <i>Interdisciplinary Applied Mathematics</i> , 2016, , 343-360.	0.2	0
786	Array of translational systems pharmacodynamic models of anti-cancer drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 549-565.	0.8	15
787	Bridging the Gap Between <i>In Vitro</i> Dissolution and the Time Course of Ibuprofen-Mediating Pain Relief. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3658-3667.	1.6	13
788	Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. <i>Scientific Reports</i> , 2016, 6, 23458.	1.6	35
789	Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 92-107.	1.1	6
790	Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 385-393.	0.8	6

#	ARTICLE	IF	CITATIONS
791	Systems pharmacology â€œ Towards the modeling of network interactions. European Journal of Pharmaceutical Sciences, 2016, 94, 4-14.	1.9	101
792	Pharmacokinetic/pharmacodynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Î” <sup>9</sup> -tetrahydrocannabinol challenge tests. British Journal of Clinical Pharmacology, 2016, 81, 713-723.	1.1	4
793	PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. Journal of Pharmacological and Toxicological Methods, 2016, 79, 34-44.	0.3	6
794	Anesthetic Drugs Pharmacokinetics and Pharmacodynamics. , 2016, , 373-394.		0
795	Establishing the Quantitative Relationship Between Lanreotide AutogelÂ®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors. AAPS Journal, 2016, 18, 703-712.	2.2	18
796	Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 253-265.	1.5	10
797	Modeling Respiratory Depression Induced by Remifentanyl and Propofol during Sedation and Analgesia Using a Continuous Noninvasive Measurement of pCO <sub>2</sub> . Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 563-573.	1.3	16
798	Type-2 fuzzy sets applied to multivariable self-organizing fuzzy logic controllers for regulating anesthesia. Applied Soft Computing Journal, 2016, 38, 872-889.	4.1	36
799	Modelling the doseâ€“response relationship: the fair share of pharmacokinetic and pharmacodynamic information. British Journal of Clinical Pharmacology, 2017, 83, 1240-1251.	1.1	5
800	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clinical Pharmacokinetics, 2017, 56, 1219-1230.	1.6	96
801	Effects of different base agents on prediction of skin irritation by sodium lauryl sulfate using patch testing and repeated application test. Toxicology, 2017, 382, 10-15.	2.0	5
802	Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet. European Journal of Pharmaceutical Sciences, 2017, 109, S39-S46.	1.9	25
803	Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Drug Discovery Today, 2017, 22, 1447-1459.	3.2	18
804	Current mathematical models for cancer drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 1-15.	2.5	15
805	Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia, 2017, 72, 16-37.	1.8	170
806	Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	65
807	An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 499-518.	0.6	6
808	Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study. Clinical Pharmacokinetics, 2017, 56, 371-381.	1.6	9

#	ARTICLE	IF	CITATIONS
809	Clinical pharmacokinetics of Azilsartan medoxomil for the treatment of cardiovascular disease: A review. IOP Conference Series: Materials Science and Engineering, 2017, 263, 022032.	0.3	1
810	Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents. Korean Journal of Anesthesiology, 2017, 70, 500.	0.9	28
811	Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. Anesthesiology, 2018, 128, 1107-1116.	1.3	3
812	An Adaptive Monitoring Scheme for Automatic Control of Anaesthesia in dynamic surgical environments based on Bispectral Index and Blood Pressure. Journal of Medical Systems, 2018, 42, 95.	2.2	12
813	Pharmacokineticâ€“pharmacodynamic modeling to study the anti-dysmenorrhea effect of Guizhi Fuling capsule on primary dysmenorrhea rats. Phytomedicine, 2018, 48, 141-151.	2.3	31
814	Propofol Pharmacodynamics and Bispectral Index During Key Moments of Awake Craniotomy. Journal of Neurosurgical Anesthesiology, 2018, 30, 32-38.	0.6	20
815	Evidence of hysteresis in propofol pharmacodynamics. Anaesthesia, 2018, 73, 40-48.	1.8	21
816	On Dr Dick Climie and Dr Jack Thomas, and the Genesis of Chemical-Clinical Pharmacology in Australian Anaesthesia Research. Anaesthesia and Intensive Care, 2018, 46, 3-13.	0.2	0
817	Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 414-424.	1.3	3
818	Outcome-Driven Personalized Treatment Design for Managing Diabetes. Interfaces, 2018, 48, 422-435.	1.6	14
819	Hybrid multiparametric model predictive control with application to the neuromuscular blockade. , 2018, , .		0
821	A Bayesian Kâ€“PD model for synergy: A case study. Pharmaceutical Statistics, 2018, 17, 674-684.	0.7	4
822	Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials. Journal of Clinical Pharmacology, 2018, 58, 1284-1294.	1.0	9
823	Modeling the pharmacokinetics and pharmacodynamics of sevoflurane using compartment models in children and adults. Paediatric Anaesthesia, 2018, 28, 834-840.	0.6	13
824	An engineering oriented approach to physiologically based pharmacokinetic and pharmacodynamic modeling. Computer Aided Chemical Engineering, 2018, 42, 37-63.	0.3	5
825	Total Intravenous Anesthesia and Target-Controlled Infusion. , 2019, , 177-198.e3.		0
826	On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships. Scientific Reports, 2019, 9, 9619.	1.6	65
827	A novel mechanism-based pharmacokineticâ€“pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against Î²-lactamase-producing Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2020, 75, 400-408.	1.3	14

#	ARTICLE	IF	CITATIONS
828	Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 831-847.	1.5	33
829	An Adaptive Multi-critic Neuro-fuzzy Control Framework for Intravenous Anesthesia Administration. IFAC-PapersOnLine, 2019, 51, 202-207.	0.5	7
830	Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. BMC Anesthesiology, 2019, 19, 15.	0.7	6
831	Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. European Journal of Pharmaceutical Sciences, 2019, 136, 104938.	1.9	15
832	Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. British Journal of Clinical Pharmacology, 2019, 85, 1474-1483.	1.1	48
833	Neural inertia and differences between loss of and recovery from consciousness during total intravenous anaesthesia: a narrative review. Anaesthesia, 2019, 74, 801-809.	1.8	19
834	A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation. Pharmacology Research and Perspectives, 2019, 7, e00463.	1.1	4
835	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. , 2019, , 105-137.		5
836	Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 699-723.	1.2	16
837	You Say "PK"™ and I Say "No Way!"™; You Say "Keo"™ and I Say "Time to Go!"™. , 2019, , 5-13.		0
838	Principles of Quantitative Clinical Pharmacology. , 2019, , 1-13.		0
839	Pharmacokinetic and Pharmacodynamic Modelling in Anaesthesia. , 2019, , 14-28.		0
840	Pharmacokinetic and Pharmacodynamic Principles for Intravenous Anesthetics. , 2019, , 20-43.		0
841	Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European Journal of Clinical Pharmacology, 2019, 75, 351-361.	0.8	9
842	Impact of dosing schedule in animal experiments on compound progression decisions. Drug Discovery Today, 2019, 24, 371-376.	3.2	3
843	Pharmacokinetic and Pharmacodynamic Analysis of Alfaxalone Administered as a Bolus Intravenous Injection of Phaxan in a Phase 1 Randomized Trial. Anesthesia and Analgesia, 2020, 130, 704-714.	1.1	13
844	The Effect of Age on the Delivery of Intravenous Anesthesia: a Physiologically-based Modeling Approach to Pediatric Patients. Computer Aided Chemical Engineering, 2020, , 697-702.	0.3	0
845	An Integrated TK-TD Model for Evaluation of <b><i>Radix Aconitikusnezoffii</i></b> (RAK). Pharmacology, 2020, 105, 669-680.	0.9	0



#	ARTICLE	IF	CITATIONS
846	Physiological Modeling of Concentration-Effect Relationship for Nondepolarizing Neuromuscular Blocking Drugs. , 2020, 2020, 5202-5207.		0
847	Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. Frontiers in Neurology, 2020, 11, 370.	1.1	7
848	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. Clinical Cancer Research, 2020, 26, 4892-4900.	3.2	5
849	Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Frontiers in Pharmacology, 2020, 11, 997.	1.6	56
850	Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids. Pharmacological Reviews, 2020, 72, 414-438.	7.1	30
851	Pharmacokinetic and pharmacodynamic considerations of general anesthesia in pediatric subjects. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 279-295.	1.5	5
852	Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease. PLoS ONE, 2020, 15, e0229729.	1.1	7
853	Models for control of intravenous anesthesia. , 2020, , 119-166.		2
854	Entering the era of computationally driven drug development. Drug Metabolism Reviews, 2020, 52, 283-298.	1.5	25
855	Age progression from vicenarians (20â€“29Âyear) to nonagenarians (90â€“99Âyear) among a population pharmacokinetic/pharmacodynamic (PopPk-PD) covariate analysis of propofol-bispectral index (BIS) electroencephalography. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 145-161.	0.8	1
856	Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. Archives of Pharmacal Research, 2020, 43, 80-99.	2.7	12
857	100 years of modelling ligandâ€“receptor binding and response: A focus on GPCRs. British Journal of Pharmacology, 2020, 177, 1472-1484.	2.7	33
858	Timeâ€“toâ€“Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia. Journal of Clinical Pharmacology, 2020, 60, 505-514.	1.0	42
859	Clinical Pharmacology Modeling and Simulation in Drug Development. , 2021, , 243-256.		0
860	Explaining anaesthetic hysteresis with effect-site equilibration. British Journal of Anaesthesia, 2021, 126, 265-278.	1.5	13
861	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. Clinical Pharmacology and Therapeutics, 2021, 109, 658-666.	2.3	26
862	The science of pharmacokinetics: an overview and applications. , 2021, , 207-218.		0
863	Pharmacokinetics and biopharmaceutics: â€œa leader or attendantâ€”, 2021, , 17-27.		0



#	ARTICLE	IF	CITATIONS
864	Principles of pharmacokinetics and pharmacodynamics. , 2021, , 219-242.		0
865	A Mechanistic In Vivo / Ex Vivo Pharmacokineticâ€Pharmacodynamic Model of Tenofovir for HIV Prevention. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 179-187.	1.3	2
866	A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against S. pneumoniae in Mice. Pharmaceutics, 2021, 13, 469.	2.0	2
867	A population pharmacodynamic Markov mixedâ€effects model for determining remimazolamâ€induced sedation when coâ€administered with fentanyl in procedural sedation. Clinical and Translational Science, 2021, 14, 1554-1565.	1.5	13
868	Translational precision medicine: an industry perspective. Journal of Translational Medicine, 2021, 19, 245.	1.8	51
869	Robust arterial spin labeling MRI measurement of pharmacologically induced perfusion change in rat kidneys. NMR in Biomedicine, 2021, 34, e4566.	1.6	1
870	Time-Dissociated Pharmacokinetic Pharmacodynamic Model of Cyclosporine Among Malaysian Renal Transplant Recipients. Therapeutic Drug Monitoring, 2022, 44, 282-289.	1.0	0
872	Model-Based Exposure-Response Assessment for Spectinomide 1810 in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0174420.	1.4	7
873	Phase Lag Entropy as a Surrogate Measurement of Hypnotic Depth during Sevoflurane Anesthesia. Medicina (Lithuania), 2021, 57, 1034.	0.8	0
874	Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Archives of Internal Medicine, 1987, 147, 39-43.	4.3	37
875	Contribution of Modeling and Simulation in the Regulatory Review and Decision-Making: U.S. FDA Perspective. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 37-57.	0.2	6
876	Effect Site Modelling and Its Application in TCI. Advances in Experimental Medicine and Biology, 2003, 523, 239-244.	0.8	2
877	Clinical Application of Pharmacokinetic and Pharmacodynamic Models. Advances in Experimental Medicine and Biology, 2003, 523, 57-70.	0.8	2
878	Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics. , 2013, , 101-132.		9
879	A History of Neuromuscular Block and Its Antagonism. , 2014, , 671-691.		3
880	Analysis of Analgesic Trials. , 2001, , 237-266.		2
881	Mechanism-Based Pharmacodynamic Modeling. Methods in Molecular Biology, 2012, 929, 583-600.	0.4	82
882	Pharmacometrics: A Quantitative Decision-Making Tool in Drug Development. , 2020, , 71-104.		4

#	ARTICLE	IF	CITATIONS
883	Kinetics of Non-Steroidal Anti-Inflammatory Drugs in Synovial Fluid. , 1988, 24, 66-75.		10
884	Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth. Lecture Notes in Mathematics, 2013, , 225-250.	0.1	10
885	Pharmacokinetics and Pharmacodynamics in the Pediatric Patient. , 2017, , 441-516.		2
886	Pharmacokineticâ€“Pharmacodynamic Modelling of Anesthetic Drugs. , 2017, , 117-145.		1
887	Target Controlled Anaesthetic Drug Dosing. , 2008, , 425-450.		6
888	Concepts for Toxicokinetic-Toxicodynamic Modelling in Clinical Toxicology: Application to Acute Cardiac Glycoside Intoxications. Archives of Toxicology Supplement, 1992, 15, 253-256.	0.7	6
889	Time Course of Drug Effect. Handbook of Experimental Pharmacology, 1994, , 333-352.	0.9	4
890	Simultaneous modelling of pharmacokinetics and pharmacodynamics. , 1980, , 70-78.		3
891	Structure-Pharmacokinetic and Pharmacodynamic Relationships of Steroidal Neuromuscular Blocking Agents. , 1995, , 205-212.		1
893	Intravenous Drug Delivery Systems. , 2010, , 825-858.		12
894	Pharmacology of Muscle Relaxants and Their Antagonists. , 2010, , 859-911.		54
895	Anesthesia and the Renal and Genitourinary Systems. , 2010, , 2105-2134.		13
896	A377 PHARMACOKINETICS AND PHARMACOKINETIC/-DYNAMIC (PK/PD) RELATIONSHIP OF ORG 9488, THE 3-DESACETYL METABOLITE OF ORG 9487. Anesthesiology, 1997, 87, 377A.	1.3	7
897	Dose-response and concentration-response relation of rocuronium infusion during propofol-nitrous oxide and isoflurane-nitrous oxide anaesthesia. European Journal of Anaesthesiology, 1997, 14, 488-494.	0.7	8
898	Pharmacokinetic-Pharmacodynamic Model Relating Lisinopril Plasma Concentrations to Regional Hemodynamic Effects in Healthy Volunteers. Journal of Cardiovascular Pharmacology, 1996, 28, 470-478.	0.8	11
899	Pharmacokinetic-Pharmacodynamic Model Relating Spiraprilat Plasma Concentrations to Systemic and Regional Hemodynamic Effects in Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1997, 30, 253-260.	0.8	5
900	Spectral Analysis of Heart Rate Variability as a Quantitative Measure of Parasympatholytic Effect-Integrated Pharmacokinetics and Pharmacodynamics of Three Anticholinergic Drugs. Therapeutic Drug Monitoring, 1999, 21, 141-151.	1.0	37
901	Early Phase Pharmacokinetics but Not Pharmacodynamics Are Influenced by Propofol Infusion Rate. Anesthesiology, 2009, 111, 805-817.	1.3	73

#	ARTICLE	IF	CITATIONS
903	Onset of the neuromuscular block simulated in an anatomical model. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 55-63.	1.1	5
904	Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 1399-1418.	1.0	145
905	Tubocurarine and Pancuronium: A Pharmacokinetic View. <i>Anaesthesia and Intensive Care</i> , 1980, 8, 4-12.	0.2	5
906	A Normal Distribution Model for the Pharmacodynamics of Nondepolarizing Neuromuscular Blockers. <i>Anaesthesia and Intensive Care</i> , 1997, 25, 279-281.	0.2	2
907	Classical Modeling. , 2002, , .		1
908	PK Principles and PK/PD Applications. , 2009, , 59-98.		3
909	Pharmacokinetic/Pharmacodynamic Basis of Controlled Drug Delivery. <i>Drugs and the Pharmaceutical Sciences</i> , 1987, , 213-251.	0.1	11
910	Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. <i>PLoS ONE</i> , 2017, 12, e0176443.	1.1	38
911	The Kinetics of Effect of Neuromuscular Blocking Drugs.. <i>Keio Journal of Medicine</i> , 1994, 43, 27-30.	0.5	1
912	Measurement and control of neuromuscular blockade and depth of anaesthesia. , 2003, , .		8
913	Drug interaction: focusing on response surface models. <i>Korean Journal of Anesthesiology</i> , 2010, 58, 421.	0.9	34
914	Synergism between rocuronium and cisatracurium: comparison of the Minto and Greco interaction models. <i>Korean Journal of Anesthesiology</i> , 2016, 69, 341.	0.9	1
916	Targeting the Effect Site. , 2000, , 17-26.		0
917	Effect Sites of Intravenous Anaesthetic Agents. , 2000, , 27-43.		0
918	Statistical Analyses in Clinical PPK/PD Studies. Bridging Studies using NONMEM.. <i>Drug Metabolism and Pharmacokinetics</i> , 2000, 15, 363-370.	0.0	0
919	Computer-Controlled Infusion of Neuromuscular Blocking Agents. , 2000, , 159-172.		1
920	4. PK/PD èž"ãŠè©  é"". <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 177-186.	0.1	1
921	Sensitivity Analysis of Pharmacokinetic and Pharmacodynamic Models in Clinical Trial Simulation and Design. <i>Drugs and the Pharmaceutical Sciences</i> , 2002, , .	0.1	0

#	ARTICLE	IF	CITATIONS
922	Population PK/PD Approach. Japanese Journal of Biometrics, 2003, 24, S85-S98.	0.0	0
923	Prinzipien der Therapie. , 2003, , 1-39.		0
924	2. PK/PD Approach. Japanese Journal of Clinical Pharmacology and Therapeutics, 2003, 34, 259-266.		0
925	Target-Controlled Infusion in Children. Advances in Experimental Medicine and Biology, 2003, 523, 161-170.	0.8	3
926	The Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. , 2004, , 249-273.		0
927	Pharmacokinetics in Clinical Oncology. , 2005, , 77-95.		0
928	Pharmacokinetic principles. , 2006, , 101-117.		0
929	Typical PK/PD Approaches. , 2006, , 737-746.		0
930	Population Pharmacokinetics in Drug Development. , 2006, , 747-753.		0
931	PHARMACODYNAMICS. , 2009, , 203-218.		0
932	Titration of the plasma effect site equilibrium rate constant of propofol; a link method of 'Concentration-Probability-Time'. Korean Journal of Anesthesiology, 2010, 58, 231.	0.9	0
935	Increasing interest in PK and PD studies has many advantages for anesthesiologists. Korean Journal of Anesthesiology, 2011, 60, 149.	0.9	0
936	PK/PD Approaches. , 2011, , 313-328.		0
937	Pharmacokinetics and Pharmacodynamics in the Pediatric Population. , 2012, , 123-143.		0
938	Avaliação clínica de duas doses no mesmo modelo farmacocinético de propofol: estudo da perda e recuperação da consciência. Revista Brasileira De Anestesiologia, 2011, 61, 402-408.	0.6	3
939	Major Anesthetic Themes in the 1970s. , 2014, , 105-118.		0
940	Pharmacokinetic and Pharmacodynamic Modeling in Anesthesia. , 2014, , 525-539.		0
941	Pharmacokinetic and Pharmacodynamic Aspects of Continuous Infusion Anaesthesia – Concept of Minimum Infusion Rate as an Index of Equipotency for Intravenous Agents. Clinics in Anaesthesiology, 1984, 2, 223-242.	0.2	2

#	ARTICLE	IF	CITATIONS
942	Kinetics of Drug Action. , 1984, , 327-343.		3
943	Pharmacodynamic Considerations in the Development of New Drug Delivery Concepts. , 1985, , 13-33.		3
944	Molecular Mechanisms of Drug Action and Pharmacokinetic-Pharmacodynamic Models. , 1985, , 35-49.		2
945	Clinical Decision Making Using Pharmacokinetic and Pharmacodynamic Data. , 1985, , 59-93.		3
946	Möglichkeiten zur Quantifizierung der Wirkung intravenöser Anästhetika. , 1985, , 393-402.		2
949	Targeting the Effect Site with a Computer Controlled Infusion Pump. , 1991, , 185-195.		1
950	Pharmacodynamics. Developments in Critical Care Medicine and Anesthesiology, 1992, , 87-115.	0.1	0
951	Pharmacokinetic and Pharmacodynamic Modeling Applied to Anesthetic Drugs. , 1993, , 179-192.		0
952	INTRAOPERATIVE USE OF MUSCLE RELAXANTS. Anesthesiology Clinics, 1993, 11, 325-344.	1.4	4
953	Electroencephalographic Feedback Control of Anesthetic Drug Administration. , 1994, , 36-55.		0
954	Pharmacokinetics and Pharmacodynamics During Cardiac Surgery and Cardiopulmonary Bypass. , 1995, , 55-87.		1
955	Muscle Relaxants in Patients with Renal or Hepatic Failure. , 1995, , 232-248.		0
956	Model-Based Adaptive Control of Neuromuscular Blocking Agents. , 1995, , 223-233.		0
957	Kinetic-Dynamic Modelling of Neuromuscular Blockade. , 1995, , 111-114.		0
958	The Target of Control: Plasma Concentrations or Drug Effect. , 1995, , 177-184.		0
959	Pharmacokinetic-pharmacodynamic modeling of sevoflurane-induced respiratory depression in the cat. , 1998, , 121-126.		0
960	Kinetic Analysis of Drug Disposition and Response with Physiological Intervention.. Drug Metabolism and Pharmacokinetics, 1998, 13, 163-172.	0.0	0
961	New Pharmacokinetic Concepts. Developments in Critical Care Medicine and Anesthesiology, 1999, , 1-11.	0.1	0

#	ARTICLE	IF	CITATIONS
962	The Biophase Concept. <i>Developments in Critical Care Medicine and Anesthesiology</i> , 1999, , 13-18.	0.1	0
963	The Principles of Total Intravenous Anesthesia (TIVA). <i>Developments in Critical Care Medicine and Anesthesiology</i> , 1999, , 117-136.	0.1	0
964	Is Pharmacokinetics Relevant?. <i>Developments in Critical Care Medicine and Anesthesiology</i> , 1999, , 63-70.	0.1	0
965	Pharmacokinetics and Pharmacodynamics in the Pediatric Population. , 2015, , 173-193.		0
966	The Importance of Pharmacokinetic and Pharmacodynamic Models in Sustained Release Formulation. <i>Pharmacology Toxicology and Biomedical Reports</i> , 2015, 1, 5-9.	0.0	0
967	Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. , 2016, , 121-150.		1
968	Modelling and Simulation of Biological Systems in Medical Applications. , 2016, , 233-268.		0
969	Principles of Target-Controlled Infusions. , 2017, , 147-157.		0
970	Translational Aspects in Drug Discovery. , 2017, , 495-529.		1
972	Pharmacokinetic and Pharmacodynamic Modeling. , 2020, , 1-24.		1
973	A semi-compartmental model describing the pharmacokinetic-pharmacodynamic relationship. <i>Anesthesia and Pain Medicine</i> , 2020, 15, 1-7.	0.5	2
974	Population Pharmacodynamic Modeling Using the Sigmoid Emax Model: Influence of Inter-individual Variability on the Steepness of the Concentrationâ€”Effect Relationship. a Simulation Study. <i>AAPS Journal</i> , 2021, 23, 10.	2.2	2
975	Time course of drug response. , 2022, , 377-387.		0
976	Adaptive, personalized closed-loop therapy for Parkinsonâ€™s disease: biochemical, neurophysiological, and wearable sensing systems. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1371-1388.	1.4	17
980	Kinetics of Pharmacologic Response. <i>Drugs and the Pharmaceutical Sciences</i> , 1982, , 221-269.	0.1	1
981	Pharmakodynamik. , 2007, , 19-24.		0
982	Design of Therapeutic Regimens. <i>Clinics in Anaesthesiology</i> , 1985, 3, 283-291.	0.2	2
983	Neuromuscular Blocking Agents. <i>Clinics in Anaesthesiology</i> , 1984, 2, 537-550.	0.2	0

#	ARTICLE	IF	CITATIONS
984	What's New in Pharmacokinetics and Pharmacodynamics?. <i>Anesthesiology Clinics</i> , 1988, 6, 251-280.	1.4	1
986	A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 265-71.	1.1	33
988	Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. <i>Anticancer Research</i> , 2007, 27, 1237-46.	0.5	0
989	Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014, 17, 34-91.	0.9	26
990	The relationship between the target effective site concentration of rocuronium and the degree of recovery from neuromuscular blockade in elderly patients. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16369-73.	1.3	2
991	Modeling principles of protective thyroid blocking. <i>International Journal of Radiation Biology</i> , 2022, 98, 831-842.	1.0	4
992	Comparison of two pharmacokinetic-pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect. <i>British Journal of Anaesthesia</i> , 2022, , .	1.5	2
993	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3341-3350.	1.1	2
995	Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria. <i>British Journal of Pharmacology</i> , 2022, , .	2.7	1
996	The drug titration paradox: something obvious finally understood. <i>British Journal of Anaesthesia</i> , 2022, 128, 900-902.	1.5	3
998	Pharmacokinetic Principles. , 0, , 1-25.		0
999	Clinical Pharmacokinetics. , 0, , 176-197.		0
1001	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3548-3558.	1.1	8
1002	Delayed Concentration Effect Models for Dabigatran Anticoagulation. <i>Paediatric Anaesthesia</i> , 0, , .	0.6	2
1003	Optimal Timing of Intravenous Acetaminophen Administration for Postoperative Analgesia. <i>Anesthesia Progress</i> , 2022, 69, 3-10.	0.2	0
1006	The Surface Area to Volume Ratio Changes the Pharmacokinetic and Pharmacodynamic Parameters in the Subcutaneous Tissue Cage Model: As Illustrated by Carprofen in Sheep. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	2
1007	Pharmacokinetic and Pharmacodynamic Modeling. , 2022, , 1937-1960.		0
1008	Pharmacodynamic Model-based Safety Management of Eribulin-induced Myelosuppression in Patients with Breast Cancer. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	1.0	0



#	ARTICLE	IF	CITATIONS
1010	Remifentanil pharmacodynamics during conscious sedation using algometry: a more clinically relevant pharmacodynamical model. <i>British Journal of Anaesthesia</i> , 2022, 129, 868-878.	1.5	3
1011	Intranasal (<i>2R, 6R</i>)â€hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2023, 50, 169-177.	0.9	3
1012	Evaluating and predicting the correlations of hepatic concentration and pyrrole-protein adduction with hepatotoxicity induced by retrorsine based on pharmacokinetic/pharmacodynamic model. <i>Toxicology Letters</i> , 2023, 373, 152-159.	0.4	0
1013	Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 822-831.	2.3	33
1014	Altered glucose-dependent secretion of glucagon and ACTH is associated with insulin resistance, assessed by population analysis. <i>Endocrine Connections</i> , 2023, 12, .	0.8	3
1015	Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	2
1018	Anesthesia and Ancillary Drugs and the Neonate. , 2023, , 99-166.		0
1030	Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins and Nucleic Acids. , 2024, , 119-152.		0